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SUMMARY  
Crohn’s disease and ulcerative colitis are two related but distinct chronic inflammatory 
disorders of gastrointestinal tract (GIT), commonly denoted as inflammatory bowel disease 
(IBD). The main goal of the anti-inflammatory treatment of this disorder is to achieve 
maximal drug concentration in inflamed area and reduce systemic adverse effects. For this 
purpose several colon-specific drug delivery systems have been investigated. In addition, the 
design of pellets as oral drug delivery systems may provide many advantages over single unit 
preparations and thus improve patient compliance.  
It is well known that most existing treatments of IBD are associated with significant 
side effects and for this reason the formulation with a “food like” composition was designed. 
In the first part of our study, therapeutic efficiency of rutin/chitosan pellets with coatings 
based on natural polysaccharides degraded by colonic microbiota compared to 
commercialized 5-aminosalicylic acid (5-ASA) pellets was investigated. Release profiles of 
coated pellets showed a minimal drug release in simulated stomach and small intestine 
following by rapid drug release upon exposure to the colonic fluid. The results from in vivo 
testing showed that rutin attenuated efficiently inflammation in the colon and coated pellets 
were as effective as 5-ASA pellets in mitigating experimental colitis. The studies 
demonstrated that rutin administration via chitosan core coated pellets seems to be a 
promising approach for colon-specific delivery since they could interact easily with the mucin 
layer and deliver drug especially to the inflamed colonic area to relieve symptoms of IBD 
omitting side effects related to conventional treatment. 
The second objective of this thesis was to explore the impact of additional 
mucoadhesive polymer chitosan in the pellets core on the therapeutic efficiency. For this 
purpose, 5-ASA loaded pellets were produced by extrusion/spheronisation method and 
subsequently coated with pH-sensitive polymer Eudragit® FS. No drug release at pH 1.2 
within 2 h, and release as intended in the simulated distal ileum and colon was observed. 
Chitosan-core pellets showed efficient mucoadhesive properties in ex vivo bioadhesion testing 
which were also confirmed by increased concentration of 5-ASA metabolite in the colonic 
tissues in rats. The pellets were tested in preexisting colitis and the results revealed significant 
attenuation of the colonic inflammation. We can conclude, that bioadhesive chitosan-core 
pellets showed additional beneficial properties for colonic 5-ASA delivery in the treatment of 
IBD over marketed dosage formulation. 
  XII 
SHRNUTÍ 
Crohnova choroba patří spolu s ulcerózní kolitidou mezi tzv. nespecifické střevní 
záněty. Hlavním cílem protizánětlivé léčby je dosažení maximální koncentrace léčivé látky 
v místě zánětu a snížení výskytu systémových nežádoucích účinků. Za tímto účelem bylo 
vyvinuto několik lékových transportních systémů pro kolon. Mezi nimi, pelety představují 
sofistikovanou lékovou formu přinášející nespočet výhod oproti tradičním lékovým formám.  
Je všeobecně známo, že většina stávající léčby nespecifických střevních zánětů je 
spojena s významnými vedlejšími nežádoucími účinky. Z tohoto důvodu se první část 
experimentu zaměřila na výrobu pelet obsahujících rutin, přírodní flavonoid 
s protizánětlivými účinky. Taktéž obal pelet byl složen z přírodních polysacharidů 
degradovatelných enzymy střevní mikroflóry. Disoluční studie ukázaly minimální uvolnění 
rutinu v prostředí simulujícím žaludek a tenké střevo. Naproti tomu v disolučním médiu 
napodobujícím podmínky tlustého střeva došlo k rychlému a úplnému uvolnění léčivé látky. 
Výsledky z in vivo testování naznačují, že podání rutinu vede ke znatelnému potlačení 
experimentálně vyvolané kolitidy a rutinové obalené pelety jsou stejně tak účinné jako 
komerčně vyráběné pelety obsahující kyselinu 5-aminosalicylovou (5-ASA). Naše studie 
prokázala, že  rutinové pelety s chitosanovým jádrem se zdají být slibným přínosem pro 
lékové transportní systémy pro kolon a léčbu nespecifických střevních zánětů, neboť 
zaručující uvolnění léčivé látky v místě zánětu, mají mukoadhezivní vlastnosti a nevykazují 
závažné vedlejší nežádoucí účinky.   
Druhým cílem této práce bylo objasnit vliv mukoadhezivního polymeru chitosanu na 
terapeutickou účinnost pelet. Pelety obsahující 5-ASA byly připraveny metodou 
extruze/sferonizace a následně obaleny pH dependentním polyakrylátovým obalem 
Eudragitem® FS. Jádro pelet bylo složeno buď z 5-ASA a mikrokrystalické celulosy nebo byl 
ještě přidán chitosan. Z výsledků disoluční zkoušky vyplývá, že obal je schopný zabránit 
uvolnění léčiva v prvních dvou hodinách v prostředí umělé žaludeční šťávy a disoluční profil 
v prostředí simulujícím tenké střevo a kolon odpovídá požadavkům kladeným na lékové 
transportní systémy pro kolon. Pelety obsahující chitosan prokázaly výborné mukoadhezivní 
vlastnosti v ex vivo testu, které byly dále potvrzeny zvýšenou koncentrací metabolitu 5-ASA 
ve tkáni tlustého střeva potkanů. Po podání pelet potkanům s experimentálně vyvolanou 
kolitidou došlo k významnému potlačení zánětu. Z našich výsledků vyplývá, že pelety 
s chitosanovým jádrem vykazují několik výhod pro doručení 5-ASA do kolonu oproti 
registrovaným částicovým lékovým formám.    
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RÉSUMÉ 
 La maladie de Crohn et la rectocolite hémorragique  font partie des maladies 
inflammatoires chroniques de l’intestin (MICI). Le principal objectif des traitements anti-
inflammatoires est de favoriser la délivrance du principe actif localement, spécifiquement sur 
les zones enflammées et de limiter les effets indésirables.  Ainsi, plusieurs systèmes à 
libération colonique de molécules actives ont été développés. Parmi eux, les pellets présentent 
de nombreux avantages par rapport aux formes solides unitaires conventionnelles.   
Dans un premier temps, des pellets contant une substance anti-inflammatoire naturelle 
et nutritive, la rutine, ont été développés. L’intérêt de cette molécule est de réduire 
considérablement les effets secondaires qui constituent un véritable problème dans les 
traitements actuels des MICI. Les pellets ont été enrobé avec les polysaccharides naturels se 
degradant avec la flore colonique. Les études in vitro ont démontré une libération minimale 
du principe actif au niveau de l’estomac et du petit intestin. Par contre, une libération rapide et 
totale a été observée lors de l’exposition des pellets dans les conditions du milieu colonique. 
Les résultats des tests in vivo ont demontré que la rutine a atténué considérablement 
l’inflammation au niveau de colôn et les pellets enrobés ont été aussi efficaces que les pellets 
d’acide 5-aminosalicylique (5-ASA) commercialisés. L’administration orale de rutine via les 
pellets enrobés et préparés avec le chitosan semble être une approche prometteuse, permettant 
la libération du principe actif au niveau des zones enflammées, pour le traitement des MICI 
tout en réduisant les effets secondaires.   
Le deuxième but de notre travail était d’élucider l’impact du chitosan, un polymère 
mucoadhésif, sur l’efficacité thérapeutique. Les pellets de 5-ASA ont été préparés à partir  de 
cellulose microcristalline avec ou sans chitosan. Un enrobage constitué d’un polymère pH-
dépendant, l’ Eudragit® FS, a ensuite été réalisé autour du noyau.  Les tests de dissolution ont 
montré que le principe actif n’était pas libéré du pellet après 2 h en milieu acide. En revanche,  
la libération était  rapide dans un milieu simulant l’environnement colonique. Les tests ex vivo 
avec  les pellets contenant le chitosan ont montré des propriétés mucoadhésives importantes 
qui ont été confirmées par la concentration élevée du métabolite de 5-ASA dans les tissus 
coloniques des rats. De plus, nous avons a démontré que les pellets permettaient d’atténuer de 
façon significative l’inflammation du côlon. Ainsi, les pellets bioadhésifs enrobés possèdent 
des propriétés bénéfiques supplémentaires pour la libération du 5-ASA au niveau du côlon par 
rapport à des formes multidoses commercialisées pour le traitement des MICI.   
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1.  GENERALITIES 
 
 An oral delivery system that can precisely target drugs to the colon without premature 
release in the upper GIT is important and advantageous in a number of ways (Shah et al., 
2000).  Such a delivery system is able to provide more effective local therapy of colon related 
diseases, because it avoids drug absorption through the upper GIT, minimizes drug 
concentration in the general circulation and maximizes drug levels in the diseased intestinal 
tissue (Dahan et al., 2010).  On the other hand, the colon is also viewed as the preferred 
absorption site for orally administered protein and peptides drugs due to the relatively low 
proteolytic enzyme activities and slow transit, thus such delivery system can be used to 
increase overall systemic absorption of these drugs (Arhewoh and Okhamafe, 2004).  
 Because of the distal location of colon in the GIT, a colon-specific drug delivery 
system should prevent drug release in the stomach and small intestine, and effect an abrupt 
onset of drug release upon entry into the colon. This necessitates a triggering element in the 
system that can respond to physiological changes in the colon (Yang et al., 2002). For this 
purpose, different approaches relied on the pH difference between different parts of the GIT, 
gastrointestinal transit time, enzymatic activity of the gastrointestinal microflora and 
increased luminal pressure in the colon for targeted colon delivery have been investigated and 
are detailed later (Leopold, 2001). Generally, the drug embedded within a polymeric matrix, 
or a drug reservoir (e.g., drug loaded pellet, capsule or tablet) is surrounded by a polymeric 
film coating (Karrout et al., 2009).  
 
1.1.  pH-BASED  SYSTEMS 
 The pH-dependent systems exploit the generally accepted view that pH of the human 
GIT increases progressively from the stomach (pH 2-3), small intestine (pH 6.5-7) to the 
terminal ileum (7-8) (Ashford and Fell, 1994). However, the pH of the colon drops to 5.5-7 
because of the acidification of the colonic contents caused by the products of bacterial 
fermentation (Guarner and Malagelada , 2003). Most commonly used pH-dependent coating 
polymers are methacrylic acid copolymers commonly known as Eudragit® that are insoluble 
in the stomach but soluble at pH values ranging between 5.5 and 7.0 (Khan et al., 1999). High 
individual variability in physiological pH, the similarity in pH between the small intestine and 
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the colon, and very inconsistent data of the colonic pH in disease state reported in the 
literature make pH-dependent systems less reliable and thus site-specificity of drug release in 
the colon more unpredictable (Evans et al., 1988; Nugent et al., 2001; Yang et al., 2002). 
 
1.2.  TIME-DEPENDENT  SYSTEMS 
 The location of initial drug release predominantly depends on the transit time of the 
system in the GIT (Yang et al., 2002). In this respect Pulsincap® System (Fig. I.1, Mc Neil 
and Stevens, 1990) and Time Clock® System (Pozzi et al.,1994) have been developed with the 
programmed lag time. Briefly, Pulsincap® System comprises a slowly hydrating hydrogel 
plug, and insoluble capsule body whose contents are released at times dependent on the 
dimensions of the plug (Hebden et al., 1999). Whereas, drug release from the tablet core of 
Time Clock® System occurs after a pre-determined lag phase caused by slow hydration of the 
hydrophobic coating layer and depends mainly on the thickness of this layer (Pozzi et 
al.,1994).  Even though, following gastric emptying, small intestinal transit time is fairly 
constant at 3-4 h, the retention times in the stomach are highly variable and make this 
approach complicated in predicting the accurate site of drug release (Davis et al., 1986; 
Kaniwa et al., 1988).  Additionally, the performance of a time-dependent formulation can be 
significantly affected by accelerated transit through different regions of the colon observed in 
the patients with IBD (Hebden et al., 2000). 
 
 
 
 
 
 
 
 
 
Fig. I.1: Enteric coated Pulsincap® (adapted from Mc Neil and Stevens, 1990) 
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Other alternative in time-controlled drug delivery systems involves ethyl cellulose 
coating: the drug is released in a sustained manner starting from the duodenum and 
proceeding till rectum (Sandborn, 2010). As mentioned above, transit through the small 
intestine is relatively uniform. By combining an enteric coating approach to prevent drug 
dissolution in the stomach and a delayed release element, it is possible to overcome high 
variability in gastric residence time and target drug liberation in the terminal ileum and colon 
(Friend, 2005). These systems consist of an outer coating of an enteric polymer (usually 
Eudragit® L, S, or FS) and inner coating based on Eudragit® RL and RS, ethylcellulose, or 
hypromellose (HPMC) (Fig. I.2, Gupta et al., 2001; Lecompte et al., 2005; Chickpetty et al., 
2010). 
 
 
Fig. I.2: Double coating time-dependent system 
 
1.3.  MICROFLORA-ACTIVATED  SYSTEMS 
 The colonic microflora is well recognized as an effective triggering component in the 
design of colon-specific drug delivery systems since bacteria population increase abruptly in 
the colon (over 400 distinct species having a population of 1011-1012 CFU/ml) and produces a 
wide range of enzymes that are not present or are different from those in the stomach and the 
small intestine (Simon and Gorbach, 1984; Basit, 2005; McConnell et al., 2008). Large 
number of polysaccharides, such as amylose, alginates, dextran, guar gums, inulin, pectins, 
starch etc., is stable in the upper GIT, however is specifically hydrolysed by colonic bacteria 
(Hovgaard and Brøndsted, 1996). These polysaccharides can be incorporated into the delivery 
system via film coating and matrix formation or used as drug-polymer conjugates and 
prodrugs (Vandamme et al., 2002). Thus, they pass unchanged through the stomach and small 
intestine and active drug moiety is released after enzymatic bond cleavage in the colon. The 
enzymatic controlled systems seem to be very promising since they could avoid the 
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drawbacks inherent in pH- and time- dependent systems. Nevertheless variations in enzymatic 
activity leading to variability in drug cleavage or drug release in Crohn’s disease (CD) 
patients have been observed (Carrette et al., 1995; Yang et al., 2002).    
Codes™ represents another more complex formulation which relies on the conversion 
of lactulose to organic acids by colonic bacterial enzymes as shown and explained in Fig. I.3 
(Watanabe et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. I.3: Schematic of the CODES™ formulation (adapted from Katsuma et al., 2002). 
Typical configuration consists of a core tablet coated with three layers of polymer coatings. 
CODES™ remains intact in the stomach due to the outer coating (Eudragit® L). Once the unit 
passes into the duodenum, enteric and barrier (HPMC) coating dissolves exposing the inner 
Eudragit® E coating which is slightly permeable and swellable in the small intestine. Upon 
entry into the colon, lactulose inside core tablet dissolves and diffuses through the coating. 
This disaccharide is enzymatically degraded into short chain fatty acids by colonic bacteria. 
This lowers the local pH, Eudragit® E dissolves and subsequently drug is released. 
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1.4.  PRESSURE-CONTROLLED  SYSTEMS 
 As a result of strong peristaltic waves, increased luminal pressure occurs in the colon 
than in the small intestine providing a potential trigerring mechanism for colon-specific drug 
delivery (Shameem et al., 1995). Pressure-controlled colon delivery capsule has been 
introduced by Niwa et al. (1995) and consists of a capsular shape suppositories with an inner 
ethylcellulose coating. Disintegration of the formulation depends on the thickness of the 
ethylcellulose film. However, it should be noted that major peristaltic waves occur 
physiologically only once or twice a day and therefore the exact time of drug release cannot 
be accurately predicted. Moreover, drug release could be significantly affected by colonic 
disorders such as diarrhoea (Leopold, 1999). 
 
 
2.  PELLETS 
 
In the past three decades, multiple unit drug delivery systems like e.g. pellets have gained 
increasing attention in different pharmacological applications. The pellet based systems have 
been recognized as an efficient way for IBD treatment compared to single unit forms in order 
to prolong colonic passage time in patients suffering from diarrhoea (Collnot et al., 2012). As 
well, delayed-onset sustained-release pellets have been proposed according to the concept of 
chronotherapy to improve the pharmacotherapy of cardiovascular diseases (Michelson 1991). 
Besides, pellets as pulsatile drug delivery system present an interesting approach for 
antidiabetic drugs with short biological half-life requiring multiple dosing or for treating 
nocturnal bronchial asthma or angina pectoris (Maroni et al., 2005; Piao et al., 2009). 
Additionally, sustained-release pellets have been developed for drugs with short half-life, for 
example ambroxol, diclofenac sodium, flucloxacillin, paracetamol, for the purpose of 
improving patient compliance (Bowyer and Cumberland, 1994; Grassi et al., 2003; Kramar et 
al., 2003; Chi et al., 2010). Also, pellets offer more flexibility to body weight dose adaptation 
and therefore represent an alternative to tablet breaking in pediatrics (Kayumba et al., 2007). 
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2.1.  PELLETS  AS  SOLID  DOSAGE  FORMS 
 Historically, the term “pellet” has been used by a number of industries to describe a 
variety of agglomerates produced from diverse raw materials using different processing 
conditions (Ghebre-Sellassie and Knoch, 2002). Pharmaceutical pellets are small, free 
flowing, spherical or semi-spherical units with a narrow size distribution, typically varying 
between 500 and 1500 μm in size which can be obtained through agglomeration of fine 
powders or granulates of active ingredients and excipients using several pelletization methods 
(Ghebre-Sellassie, 1989). Pellets offer a high degree of flexibility in the design and 
development of oral dosage forms and are primarily produced for manufacturing of 
controlled-release dosage forms with gastroresistant or sustained-release properties (Gryczova 
et al., 2008). For this purpose, they are filled into hard capsules, sachets or stick packs 
(Chopra et al., 2002). Alternatively, they are combined with suitable excipients and 
compacted into disintegrating tablets (Bashaiwoldu et al., 2011). They can also be sold in 
multidose containers and taken with a measuring spoon by the patient (Knop and 
Kleinebudde, 2005). In order to obtain a controlled release, polymeric film coatings or several 
types of matrix systems are commonly used (Tapia et al., 1993; Van Savage and Rhodes, 
1995). The spherical shape of pellets without any edges is ideal for the application of coatings 
with respect to the low surface-to-volume ratio for a given particle size (Larsen et al., 2003). 
 
2.2.  PELLETS  VERSUS  SINGLE  UNIT  FORMS 
  The use of pellets in controlled-release oral solid dosage forms provides several 
advantages over monolithic single-dose units such as tablets: 
PHARMACOLOGICAL 
 After swallowing, the pellets are widely and more uniformly dispersed in the GIT 
contents with a consequent reduction in local drug concentration and thus less local 
irritation of the gastrointestinal mucosa on the one hand  and increased contact 
between drug and GIT surface and thus more uniform drug absorption and improved 
bioavailability on the other hand (Washington et al., 2001; Cheng et al., 2004). 
 The pellets appear to be less influenced by the physiologic factors, such as the gastric 
emptying and intestinal transit. More predictable and reproducible gastrointestinal 
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transit time provide more uniform drug release. In addition, pellets are continuously 
emptied from the stomach during the digestive period compared to the non-
disintegrating tablets which are emptied during the interdigestive period (Hardy et al., 
1985; Goracinova et al., 2012). 
 Due to smaller particle size, the pellets pass through the GIT easily, leading to less 
inter- and intra-subject variations in the pharmacokinetic parameters and moreover are 
retained in the ascending colon for a relatively long period of time (Hardy et al., 
1985). 
 The unintentional disintegration of certain single unit formulation (due to 
manufacturing defects, abrasion with food in the stomach, etc.) and consequently 
serious problems with dose dumping, risk of side effects and systemic toxicity are 
considerably less with pellets  because the release failure of the individual unit hardly 
affects the total release behavior of multiparticulate system (Washington et al., 2001; 
Chopra et al., 2002; Cheng et al., 2004). 
 The pellets can be re-obtained easily by opening the capsule or dispersing the tablet in 
water. This allows more facile swallowing for children and elders or even 
administration via nasogastric feeding tubes (Steiner, 2011).  
TECHNOLOGICAL 
 Pellets possess low friability and narrow particle size distribution. Owing to their 
smooth surface morphology and spherical shape pellets can be easily coated or are 
ideal for powder layering. Pellets offer the possibility of accurate volumetric dosing on 
tablet presses or uniform packing on capsule filling machines due to good flow 
properties (Reynolds, 1970, Gryczova et al., 2008). 
 Pelletization process results in an improvement of the uniformity of the content thanks 
to the prevention of segregation of co-agglomerated components (Gu et al., 2004). 
 Manipulation with pellets prevents dust formation resulting in an amelioration of the 
process safety (Ramaker, 2001).  
 Incompatible drugs can be processed separately and mixed later. Drugs with different 
release pattern can be combined in the same dosage form or pellets with different 
release mechanisms can be mixed to give a new modified release profile of a single 
dose (capsule, sachet) (Steckel and Mindermann-Nogly, 2004). 
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 High dose of drug can be incorporated into the pellets (Wesseling and Bodmeier, 
2001). 
 Pellets provide improved drug stability against external factors such as moisture, air 
and light (Fitzpatrick et al., 2006). 
 
2.3.  PELLETIZATION TECHNIQUES 
 Pelletization is often referred to as a size-enlargement process that involves the 
manufacture of agglomerates with a relatively narrow size range, and is used in various 
industries, such as agriculture, mineral processing, food and detergent industry. Several 
methods in the pharmaceutical industry are used for pellet preparation. The most commonly 
employed and intensely investigated pelletization processes are layering of the drug solution, 
suspension or powder on the inactive cores, extrusion/spheronization (E/S) and 
rotoagglomeration. Extensive research has focused as well as on the development of novel 
manufacturing approaches that use innovative formulations and processing equipment, such 
as spray drying, or spray congealing, hot-melt extrusion, cryopelletization, etc. (Ghebre-
Sellassie and Knoch, 2002; Dukić-Ott et al., 2009; Hirjau et al., 2011).   
 
2.3.1.  Layering 
2.3.1.1.  Dry powder  
Formulation of multiparticulates by powder layering process comprises the deposition 
of successive layers of dry powder of drug, excipients or both on preformed nuclei or cores 
with the help of a binding liquid. Since finely milled dry powder and binding liquid are 
applied simultaneously, this process requires specialized equipment. Conventional coating 
pan, a machine that has been used primarily for sugar coating, was the first equipment utilized 
to manufacture pellets. However, the degree of mixing is very poor and the drying process is 
not efficient. Given that tangential spray or centrifugal fluid-bed granulators have been 
developed to overcome these significant limitations. During a layering process, centrifugal 
force, fluidization air velocity, and gravity force act in concert to generate a spiral, rope-like 
motion of the particles in the product bed. Loss in the spiral rope-like motion, caking and 
severe particle attrition represent the serious problems in this technique. Fig. I.4 shows 
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principle of powder layering process. In the initial stages, the drug particles are bound to the 
starter seeds and subsequently to the forming pellets with the help of liquid bridges originated 
from the sprayed liquid, eventually replaced by solid bridges. Successive layering continues 
until the desired pellet size is reached. Throughout the process, it is extremely important to 
maintain equilibrium between the binder liquid application rate and the powder delivery rate 
in order to avoid overwetting and agglomeration or dust generation. The most attractive 
features of this technique are the uniform distribution of the powder on cores and the high 
drying efficiency of the binder solution, as well as the possibility of applying the successive 
functional film coating using the same equipment. In spite of interesting possibilities, powder 
layering still presents some drawbacks. This process requires a great deal of repetition of 
wetting and powdering operations and is thus time consuming. Moreover, undesired 
agglomeration and adhesion of pellets to the wall of the coating equipment can occur 
(Nastruzzi et al., 2000; Ghebre-Sellassie and Knoch, 2002; Varshosaz et al., 2009). 
 
 
 
 
 
 
 
Fig. I.4: Principle of powder layering process (downloaded from Glatt®) 
 
2.3.1.2.  Solution/suspension  
 Solution/suspension layering involves the deposition of successive layers of solutions 
and/or suspensions of drug substances and binders on starter seeds, which may be inert 
materials or crystals/granules of the same drug. The process can be carried out in 
conventional coating pans, fluid-bed centrifugal granulators, or Wurster coaters. Its efficiency 
and the quality of manufactured pellets are in part related to the type of equipment used. The 
Wurster coating process, which was invented about 30 years ago, had evolved into ideal 
equipment owing to the high drying efficiency, cylindrical partition located in the product 
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chamber and orifice plate. The obtained pellets are uniform in size distribution and exhibit 
very good surface morphology. Homogeneous layering of drug substances is consistently 
achieved using this method nevertheless only low drug loaded pellets can be produced. The 
quantity of starter cores, the fluidization air volume and the well-organized particle movement 
are the critical parameters in this process. Besides, the evaporation rate of the application 
medium should neither impair binder effectiveness nor lead to overwetting and subsequent 
agglomeration. It is important to keep in mind that with increasing size of the forming pellets, 
the mass in the bed rises, and so it is necessary to continuously augment the fluidization air 
volume to provide optimum expansion and mixing of the product bed. During processing 
(Fig. I.5), all the components of the formulation are first dissolved or suspended in a 
appropriate quantity of application medium to provide a formulation with the desired 
viscosity and is then sprayed onto the product bed. The sprayed droplets immediately impinge 
on the starter seeds and spreads evenly on the surface. In a drying phase, dissolved materials 
precipitate and form solid bridges that would hold the formulation components together as 
successive layers on the starter seeds. The process continues until the desired quantity of drug 
substance are achieved (Ghebre-Sellassie and Knoch, 2002).  
 
 
 
 
 
 
 
Fig. I.5: Principle of suspension layering process (downloaded from Glatt®) 
 
2.3.2.  Extrusion/spheronization 
Historically, the concept of E/S as a pelletization technique has been developed in the 
early 1960s and widely used in the plastics and food industries. It found its way into the 
pharmaceutical industry in 1964 with the invention of the spheronizer also known as a 
marumizer by Nakahara. Marumizer consists of a static cylinder or stator and a rotating 
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friction plate with a grooved surface at the base (Fig. I.6). The unevenness serves as the 
means for cutting and rubbing material which travels in the path of arrow B.  
 
Fig. I.6: Marumizer patented by Nakahara, demonstration of particles moving, indented 
plate; A-plate turning direction, B-path of material travelling (adapted from Nakahara, 
1964) 
E/S is a multistage process allowing production of pellets with uniform size from wet 
granulates. The method was first reported by Renolds (1970) and by Conine and Hadley 
(1970) and involves the following main steps: homogenization and wetting, extrusion, 
spheronization and drying. This technology enables the manufacture of pellets with a high 
drug loading up to 90 % but it also can be used to produce extended-release matrix type 
pellets in a single step avoiding subsequent film coating. The produced pellets posses low 
friability, good flow properties, and a spherical to slightly oval shape. The characteristics and 
quality of the final pellets are dependent on the physicochemical properties of the active 
pharmaceutical ingredient, excipients and process variables which are shown in Fig. I.7   
(Nakahara, 1964; Ghebre-Sellassie and Knoch, 2002; Trivedi et al., 2007). 
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Critical factors in extrusion-spheronization
Properties of the drug substances and excipients
Process variables
Mixing
Extrusion
Spheronization
Particle size, size distribution, shape and surface area
Polymorfism
Density
Solubility
Moisture sorption capacity
Type and amount of binder
Uniform distribution of binder liquid
Rate of liquid addition
Mixing time and speed
Extruder type 
Extruder speed
Diameter of the orifice and thickness of the die
Material feeding rate
Spheronization time and speed
Spheronizer load
Friction plate design
Groove width of the plate
Drying Drying time and rate
Drying technique
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. I.7: Critical factors in E/S (adapted from Ghebre-Sellassie and Knoch, 2002; Trivedi et 
al., 2007) 
 
Mixing or blending of dry powders is the first step of the extrusion/spheronization process when 
the drug is mixed with one or more excipients in a blender. Subsequently, an adequate amount of 
binding liquid is added to the dry powder mixture at an appropriate rate to obtain a wet mass. The 
quantity of liquid should be sufficient to provide plasticity to the resulting extrudates.  During this 
step the evaporation of the fluid phase should be restricted to a minimum and the homogeneous 
distribution of granulation liquid throughout the wet mass should be achieved. The dry blending 
and wet mixing are generally carried out in the same equipment, such as a planetary mixer, sigma 
blade mixer, continuous granulator or a high-shear mixer (Baert and Remon, 1993; Vervaet et al., 
1995; Trivedi et al., 2007).   
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Extrusion, the second step, is a continuous process that can be defined as a molding process in 
which the material is forced to pass through a die or mold with the numerous apertures to create 
cylinders or rod-shaped masses called extrudates. The granulated mass must be plastic and 
sufficiently cohesive and self-lubricating during extrusion. The diameter of the extrudate 
segments and the final size of the spheroids depend on the diameter of the opening in the 
extruder screen. A variety of extruders exists. In screw-fed extruders (Fig. I.8), screws rotate 
along the horizontal axis and transport the wet mass from the hopper towards the die. Axial 
extruders have a die plate positioned perpendicularly at the end of the screw and tend to 
produce extrudates with slightly higher densities whereas in radial extruders material is 
extruded radially through screens mounted around the horizontal axis of the screws, they have 
higher throughput but produce less dense extrudates. Nevertheless, the increase in product 
temperature is negligible and thus it is a suitable method to extrude thermolabile drug 
substances. Twin-screw extruders provide better material transport characteristics and higher 
capacity or throughput than single-screw extruders (Hicks and Freese, 1989; Newton, 2002).  
Fig. I.8: Schematic view of axial and radial type of screw extruder (adapted from Vervaet 
et al., 1995) 
Gravity-fed extruders (Fig. I.9A) are equipped with two rollers that apply pressure on the wet 
mass which moves through the extruder by gravitational force. In ram extruders (Fig. I.9B), a 
piston displaces and forces the wet mass through a die at the end. These extruders are used for 
extrusion of wax-like substances. The ideal extrudate should have sufficient mechanical 
strength to retain the shape without crumbling into powder, but also be brittle enough to be 
broken down during spheronization. In addition, it should possess sufficient plasticity to be 
rolled into spheres (Fielden et al., 1992; Hirjau et al., 2011).  
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Fig. I.9: Schematic view of gravity-fed extruders (A) and ram extruder (B) (adapted from 
Vervaet et al., 1995) 
Spheronization takes place in a spheronizer which consists of a cylindrical bowl with a 
bottom rotating friction plate. Two commonly known groove patterns of plate are crosshatch 
geometry, in which the grooves intersect each other at 90° angle, and radial geometry, in 
which the grooves spread out radially from the center (Fig. I.10). The extrudates are 
spheronized by interparticle collisions and particle-to-wall frictional forces. The grooved plate 
moves the extrudates in such a way that they scramble back and forth in a spiraling motion 
onto the rotating bed. The frictional force on the material generated by this movement first 
breaks the extrudates into small cylinders, which then spheronize into spheres. There are two 
well-known models that describe this transition mechanism. According to Rowe’s model (Fig. 
I.11), rounding of the cylinders starts with edges to form rounded ends and continues with the 
conversion into dumbbell-shaped pellets, elliptical shaped pellets and finally into spheres. 
However, Baert’s model (Fig. I.11) describes the transformation of cylindrical extrudates into 
rope-shaped cylinders and then into dumbbell-shaped pellets. On further twisting, the latter 
break into two spheres with cavities. The continuous movement of the pellets eventually seals 
the cavities and forms the spherical pellets. The spheronizing time is usually 2-15 min. During 
the spheronization step, it is essential that the extrudate break at appropriate length and have 
sufficient surface moisture to enhance formation of uniform spherical pellets. The degree of 
liquid saturation is critical factor and needs to be optimized. Wet mass containing low 
moisture content may generate extrudates that produce large quantities of fines during the 
spheronization step. If the moisture level is too high, the extrudate may adhere to each other, 
become sticky and form bundles of strands that fail to rotate. New types of spheronizers, so-
called air-assisted, are designed to permit a conditioned air stream to pass from beneath the 
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rotating disk through the gap or slit between the cylindrical wall and the rotating friction plate 
into the product bed which improves pellet turnover and brings about a spiral rope-like 
motion that facilitates spheronization (Rowe, 1985; Baert et al., 1993; Trivedi et al., 2007).  
Fig. I.10: Geometry of crosshatch (A) and radial (B) spheronization plate (adapted from 
Vervaet et al., 1995) 
 
Fig. I.11: Pellet-forming mechanisms according to Rowe (upper row: I-cylinder; II-
cylinder with rounded edges; III-dumbbell; IV-ellipse; V-sphere) and Baert (lower row: 
I-cylinder; II-rope; III-dumbbell; IV-sphere with a cavity outside; V-spheres) (adapted 
from Vervaet et al., 1995) 
The final step of the E/S is drying. Because relatively large amounts of water or solvent are 
incorporated into the formulation, the final pellets contain significant quantities of residual 
moisture and are oven-dried or dried in a flui-bed dryer or at room temperature before further 
processing. Porosity of pellets may be affected by different drying techniques depending on 
the rate of water evaporation (Vervaet et al., 1995; Bashaiwoldu et al., 2004). 
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2.3.3.  Rotoagglomeration 
Rotoagglomeration is a newer method of pellet preparation. Homogenized dry powder 
mixture of the drug and excipients is wetted and due to the centrifugal, fluidization and 
gravity forces, is turned into the spheres (Fig. I.12). A centrifugal force is provided by a 
rotating disc, the main piece of the equipment, which throws the pellets towards the wall of 
processing chamber. Air via a slit between the disc and the wall of the chamber moves the 
particles in a vertical direction. As the fluidizing force decreases with the distance above the 
slit, the pellets fall towards the bottom of the disc. The centrifugal force is in relation with the 
rotation speed of the disc, while the vertical distance for which the particles move is 
dependent on the air velocity and volume. As powders come  in contact with a liquid phase, 
they form agglomerates or nuclei, which initially are bound together by liquid bridges. These 
are subsequently replaced by solid bridges, which are derived from the hardening binder. The 
nuclei formed collide with other adjacent nuclei and coalesce to form larger nuclei or pellets. 
The coalescence process continues until a condition arises in which bonding forces are 
overcome by breaking forces. At this point, coalescence is replaced by layering, whereby 
small particles adhere on much larger particles and increase the size of the latter until 
pelletization is completed (Vertommen and Kinget, 1997; Kristensen et al., 2000; Ghebre-
Sellassie and Knoch, 2002; Hirjau et al., 2011).  
 
 
 
 
 
 
 
Fig. I.12: Principle of direct pelletizing (downloaded from Glatt®) 
The moisture content is particularly critical because it determines whether nucleation, 
coalescence or layering occurs (Fig. I.13). Using a rotary processor, it is possible to produce, 
to dry and, if desired, to coat pellets in the same equipment. It is the main advantage of this 
technique, because dust problems and the contamination risks can be avoided, and time, 
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equipment, energy, laboratory space, and machine operators can be saved. Moreover, pellets 
produced by this method were reported to be of the same quality as pellets produced by the 
conventional multi-step E/S process. Additionally, pellets of homogeneous matrix structure 
and high drug loading of up to 65 % can be achieved. The particle size distribution is however 
broader than that resulting from the above mentioned two methods (Robinson and 
Hollenbeck, 1991; Vetchý and Rabišková, 2002; Krejčová et al., 2006). 
 
 
 
 
 
 
 
Fig. I.13: Schematic representation of the mechanisms of nucleation, coalescence and 
layering (adapted from Sastry et al., 2003) 
 
2.3.4.   Spray drying, spray congealing 
 Spray drying and congealing are based on globulation. The droplet sizes in both 
processes is kept small to maximize the rate of evaporation or congealing, and consequently 
the particle size of the pellets is usually very small. During spray drying, a drug solution or 
suspension i sprayed, with or without excipients, into a hot air stream to generate dry and 
highly spherical particles.  As the atomized droplets come in contact with hot air, evaporation 
of the application medium is initiated. This drying process continues through a series of 
stages whereby the viscosity of the droplets constantly increases until finally almost the entire 
application medium is driven off and solid particles are formed. Generally, spray-dried pellets 
are homogenous, approximately spherical, nearly uniform in size and tend to be porous. This 
technique is usually employed to improve the dissolution rates and hence, the bioavailability 
of poorly soluble drugs. Spray congealing is a process in which a drug is allowed to melt, 
disperse or dissolve in hot melts of gums, waxes, fatty acids or other melting solids. The 
dispersion is then sprayed into a stream of air and other gases with a temperature below the 
melting point of the formulation components, to provide spherical pellets. Because the 
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process does not involve evaporation of solvents, the produced pellets are dense and 
nonporous (Ghebre-Sellassie and Knoch, 2002; Hirjau et al., 2011). 
 
2.4.  CHARACTERISATION  OF  PELLET  PROPERTIES 
The properties of pellets are listed in Table I.1 together with different evaluation 
methods (Knop and Kleinebudde, 2005). 
Table I.1: Properties of pellets 
Property Requirements Analytical methods 
Particle shape, sphericity Like a sphere, aspect 
ratio close to 1 
Image analysis 
Surface texture Smooth Image analysis, SEM 
Mean particle size Between 0.5 and 1.5 
mm 
Sieve or image analysis 
Particle size distribution Narrow Sieve or image analysis 
Porosity Low Mercury intrusion, true and bulk 
densities 
Density High Bulk and tapped density determination 
Mechanical strength High Friability tests, breaking force tests 
Flow properties (very) good Angle of repose, flow rate estimation, 
compressibility index, Hausner’s ratio 
Drug content From very low to 
more than 95 % 
Dependent on the drug 
Drug release From immediate to 
controlled release 
Dissolution tests 
 
2.4.1.  The pellet size, size distribution and shape 
 Shape and size are important parameters when characterising pellets for modified 
release film coating. Equally, size has a major effect on drug release from coated pellets due 
to the natural correlation between size and surface area of pellets (Larsen et al., 2003). The 
size of pellets can be determined using a variety of parameters: particle size distribution, mean 
diameter, geometric mean diameter, inter-particle range, mean particle width and length. The 
sieve analysis is the oldest, simplest and best-known method.  Despite new developments in 
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the field of optical particle measuring instruments it remains a proven, reliable and 
inexpensive method. The particle size distribution is defined via the mass or volume. Sieve 
analysis is used to divide the particulate material into size fractions and then to determine the 
weight of these fractions. During sieving the sample is subjected to horizontal or vertical 
movement carried out with sieve shakers. Depending on the size the individual particles either 
pass through the sieve mesh or are retained on the sieve surface. The tests sieves are arranged 
in a stack with the largest mesh openings at the top of the stack and a collector pan at the 
bottom. The sample is placed on the top sieve. The results are expressed as the percentage of 
the weight retained on each sieve size. Mean particle diameter can be calculated by applying 
the following formula (Haznos et al., 1992):  
             đ = Σxini  / 100 [μm]          (1) 
where xi is the mean of the upper and the lower limits of the sieve fraction and ni is the 
weight percentage of the i sieve fraction. 
In this way a relatively broad particle size spectrum can be analyzed quickly and reliably (The 
Basic Principles of Sieve Analysis). 
The image analysis represents a common analytical procedure to evaluate simultaneously the 
size, shape and surface morphology of pellets (Tapia et al., 1993).  The main advantage of this 
technique is that it could describe the non-spherical particle using the longest and shortest 
diameters, perimeter and projected area. Measuring each particle allows the user unmatched 
flexibility for calculating and reporting particle size results. Podczeck et al. (1999) stated that 
a minimum of 100 pellets should be analysed for mean pellet size estimation. Particle shape 
parameters such as roundness, aspect ratio, and compactness are used to describe particle 
morphology (Horiba Scientific). The filling of pellets into hard gelatin capsules appears 
generally possible as long as the pellets approach an aspect ratio below 1.2 and do not show 
large amounts of surface irregularities (Podczeck et al., 1999). The equipment consists of a 
stereomicroscope equipped with black/white video camera. A cold light source is used to 
illuminate the pellets against a black surface. The captured images are analyzed by computer 
software. Pellet sphericity is calculated from the determined area and perimeter according to 
the following formula (Cox, 1927):  
S = 4π x area / perimeter2                                                    (2) 
 By employing image analysis a relatively large number of pellets can be measured in a 
limited time (Larsen et al., 2003). 
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2.4.2.  Density and porosity of pellets  
 The density of a material is defined as its mass per unit volume:  
 = m / V [g/cm3]                                                         (3) 
While the mass is exactly determined by weighing, the volume can vary. This leads to define 
various types of volumes and densities (Table I.2) (Turchiuli and Castillo-Castaneda, 2009).  
Table I.2: Definition of various types of volumes and densities 
Volume/Density Volumes included 
Pellets Solid material 
Intra-particular pores 
Inter-particles 
voids Closed pores Open pores 
True x    
Apparent x x   
Bulk x x x x 
Tapped x x x x 
 
The bulk density of a solid is often very difficult to measure since the slightest disturbance of 
the bed may result in a new bulk density. Bulk density is determined by measuring the 
volume (V0) of a known mass of pellets sample (approximately 100 g) that has been passed 
without compacting into a dry graduated 250 ml cylinder and leveled carefully. Calculated 
bulk density is expressed in g per ml (USP, 2011). 
Tapped density is achieved by mechanically tapping a measuring cylinder containing a pellet 
sample. After observing the initial volume, the cylinder is tapped 500 times initially and the 
tapped volume (Va) is read to the nearest graduated unit. The tapping an additional 750 times 
is repeated and Vf measured. If the difference between the two volumes is less than 2 %,  Vf, 
is the final tapped volume. The tapping is repeated in increments of 1250 taps, until the 
difference between succeeding measurements is less than 2 % (USP, 2011).  
A comparison of the bulk and tapped densities can be used as an index of the ability of pellets 
to flow which is an important factor during the filling of pellets into hard capsules. 
Compressibility index (4) and Hausner ratio (5) are measures of the relative importance of 
interparticulate interactions. Alternatively, they may be calculated using measured values for 
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the unsettled apparent volume (V0) and the final tapped volume (Vf). Pellets with excellent 
flowing property are characterised with less significant interactions between the particles, and 
the bulk and tapped densities will be closer in value. The generally accepted scale of 
flowability is given in Table I.3 (part 2.4.3.) (USP, 2011). 
Compressibility index = 100 (ρt  - ρ0) /  ρ0  =  100 (V0  - Vf) /  V0     [%]                        (4) 
Hausner ratio = ρt /  ρ0  =  V0 / Vf                                                                                (5) 
The apparent density (ρapp) includes pores inside the particles and can be determined in a 
helium pycnometer. Helium has a very small atomic size that can permeate extremely narrow 
pores in a solid and fill the interparticular spaces, permitting the determination of the real 
volume occupied by the sample. The ratio of the dried sample weight and the volume 
measured by pycnometer gives the apparent density. The high thermal conductivity of helium 
and its ideal gas behavior at room temperature, make this technique extremely reliable and 
fast. The true density (ρs) corresponds to the density of raw substances or pellets crushed into 
the powder including also intraparticular spaces-closed pores (Omega Scientific). 
The inter-particular porosity corresponds to the voids between pellets. The total volume of 
inter-particle voids depends on the size and shape of pellets and how well they will flow. The 
inter-particular porosity could be also calculated from the values of bulk and apparent density 
(Turchiuli and Castillo-Castaneda, 2009):   
        Inter-particular porosity  = (1 – Vapp / V0) x 100 =  (1 – ρ0 / ρapp) x 100   [%]                    (6)      
The intra-particular porosity of pellets can affect the capillary action of the dissolved drug 
and consequently, influence the rate of release of drugs from the pellets. It also affects film 
deposition and formation during coating and has an impact on the pellets hardness. The intra-
particular porosity is formed by cavities and cracks within the pellets themselves and is 
defined as the ratio of void volume (Vv) and total volume (Vapp) of the pellets. The void 
volume is the difference between the total volume (Vapp) and the solid volume (Vs). It can be 
also calculated as the difference between the true (ρs) and apparent density (ρapp) (Turchiuli 
and Castillo-Castaneda, 2009):   
         Intra-particular porosity = (1 – Vs / Vapp) x 100 = (1 – ρapp / ρs) x 100 [%]                       (7) 
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2.4.3.  Flow properties of pellets 
 Some of the common methods as angle of repose, flow through an orifice and also 
compressibility index and closely related Hausner ratio mentioned above indicate the flow 
properties of pellets. The angle of repose, a static method, is commonly used characteristic 
related to interparticulate friction or resistance to movement between particles (USP, 2011). 
The pellets are placed in a conical glass funnel with a stem. The funnel is maintained upright 
so that the stem terminated 10 cm above a flat solid underlay protected from vibrations. 
Pellets flow freely out of the funnel and form a cone. Its height (h) and base diameter (d) is 
measured and the repose angle value () is calculated using the following equation (Häring et 
al., 2008): 
                                                    tan () = h / 0.5 d [˚]       (8) 
Although there is some variation in the qualitative description of powder flow using the angle 
of repose, much of the pharmaceutical literature appears to be consistent with the 
classification by Carr (1965) which is shown in Table I.3. When the angle of repose exceeds 
50°, the flow is rarely acceptable for manufacturing purposes (USP, 2011). 
Table I.3: Flow properties and corresponding angles of repose 
Flow property 
Angle of repose 
[˚] 
Compressibility 
index [%] Hausner ratio 
Excellent 25 - 30 ≤ 10 1.00 - 1.11 
Good 31 - 35 11 - 15 1.12 - 1.18 
Fair - aid not needed 36 - 40 16 - 20 1.19 - 1.25 
Passable - may hang up 41 - 45 21 - 25 1.26 - 1.34 
Poor - must agitate, vibrate 46 - 55 26 - 31 1.35 - 1.45 
Very poor 56 - 65 32 - 37 1.46 - 1.59 
Very, very poor > 66 > 38 > 1.60 
    
The flow rate through an orifice is generally measured as the mass per time flowing from any 
of a number of types of containers (cylinders, funnels, hoppers). The orifice diameter and 
shape are critical factors in determining pellets flow rate. Flow rate can be measured 
continuously using an electronic balance permitting detect momentary flow rate variations or 
in discrete samples. This method is not useful for cohesive materials. No general scale is 
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available because flow rate is critically dependent on the method used to measure it (USP, 
2011).  
 
2.4.4.  Mechanical properties of pellets 
Mechanical properties include pellet friability and hardness. Since most pellets are 
subjected to coating, it is necessary that they possess good mechanical properties in order to 
withstand the coating process. Any other handling of particulate materials in manufacturing 
and shipping, inevitably causes attrition. By determination of friability and hardness of 
pellets, information about their stability and behavior under mechanical stress can be obtained 
(Bemrose and Bridgwater, 1987).  
The pellets, accurately weighted (m1) and free of dust, are placed into a stainless steel drum of 
the abrasion tester adapted for pellet testing together with 200 pieces of 4 mm glass beads, 
and rotated for 10 min. at 20 rpm. Subsequently glass beads are separated from the pellets 
using a set of sieves, generated fines are  removed with the air stream and pellets are 
reweighed (m2). The friability, that is, the weight loss after agitation, is expressed as a 
percentage and calculated from Eq. 9 The result is the average of three runs (Dreu et al., 2005; 
Scala-Bertola et al., 2009): 
Friability = [(m1-m2)/m1] x100 [%]                                   (9) 
Tablet hardness and compression tester fitted with 5-kg load cell operated at constant speed is 
used for the assessment of pellet hardness. The hardness is defined as force necessary to crush 
the pellets under the standard conditions. Individual pellets are placed between two jaws, one 
moves, the second is fixed.  The force needed to fracture is recorded and the hardness is 
expressed in Newton, kilogram or pound (1 kg = 9.81 N = 2.2 Ib). Measurement is performed 
ten times in randomly selected pellets and the hardness mean value and the standard deviation 
are calculated (Gryczová et al., 2008). Otherwise, the hardness may be also expressed as 
tensile strength (σ) calculated applying the values for the failure load (F) and the radius of the 
pellet (R) according to Eq. 10 (Shipway and Hutchings, 1993): 
                              σ f(s) = 0.4 F/πR
2  [MPa]                                                                      (10) 
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1.  RUTIN 
 
 
Fig. II.1: Rutin structure (downloaded from wikipedia) 
Molecular formula: C27H30O16     Molar mass = 610.52 g/mol 
 
Rutin (quercetin 3-O-rutinoside) is a flavonol glycoside, composed of quercetin, glucose and 
rhamnose, widely occurring in the plant kingdom (Abdullah et al., 2008). It was first isolated 
by the German pharmacist-chemist August Weiss in 1842 from the leaves of the garden rue 
(Ruta graveolens, Rutaceae). Rutin is a yellow crystalline powder only slightly soluble in 
water (Couch et al., 1946). For pharmaceutical purposes, rutin may be obtained from green 
buckwheat (Fagopyrum esculentum, Polygonaceae) and Japanese Pagoda tree (Sophora 
japonica, Fabaceae) (Lachman et al., 2000). Extensive studies by pharmacologists have 
shown that rutin is nontoxic (Afanas'eva et al., 2001). After oral administration, rutin is hardly 
absorbed from the upper GIT owing to its highly hydrophilic sugar moieties (Fig. II.2). 
Reaching the colon, it is deglycosylated by present microbiota producing α-rhamnosidase and 
ß-glucosidase, and its aglycone quercetin is liberated. Quercetin can be absorbed easily into 
epithelial cells and most likely exerts a therapeutic effect of the parent compound. After 
intestinal absorption, quercetin enters the liver via the portal vein and is biotransformed. 
Conjugation of the polar hydroxyl groups with glucuronic acid, sulfuric acid, glycine, or 
possibly glutathione results in water-soluble conjugates. These conjugates are eliminated 
either from the liver with bile into the duodenum, or renally with the urine. In addition, 
flavonoid glucuronide and sulfate metabolites secreted into the small intestine could be 
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hydrolyzed and the liberated aglycones would then pass into enterocytes passively, 
reabsorbed again, and metabolized forming thus an enterohepatic cycling (Kim et al., 1998; 
Crespy et al., 1999; Williamson et al., 2000; O'Leary et al., 2001; Spencer et al., 2003; 
Rechner et al., 2004; Kim et al., 2005). 
Fig. II.2: Proposed pharmacokinetics of orally administered rutin (downloaded from 
Rabišková et al., 2009) 
 
The first application of rutin medicinally was in the treatment of increased capillary fragility 
and permeability (Johnson, 1946). Rutin possess antihemorrhagic activity (Formica and 
Regelson, 1995). The use of rutin has been studied in many applications, for example, 
glaucoma (Stocker, 1947), protection from injury by X-ray irradiation (Weiss and Landauer, 
2003), telangiectasia (Kushlan, 1946), protecting against cold injury (Fuhrman, 1955), 
lowering cholesterol levels (da Silva et al., 2001), hemorrhoids treatment (Squadrito et al., 
2000), etc. Rutin has antioxidant and anti-inflammatory activity (Guardia et al., 2001). 
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2.  5-AMINOSALICYLIC  ACID (MESALAZINE) 
 
                                                   
 
Fig. II.3: 5-ASA structure, zwitter ion (downloaded from wikipedia) 
Molecular formula: C7H7NO3
                                                                           Molar mass = 153.14 g/mol 
 
5-ASA, also known as mesalazine, presents light tan to pink needle-shaped odourless crystals. 
The colour may darken on exposure to air thus the preferable storage is in airlight containers. 
5-ASA is very slightly soluble in water and practically insoluble in alcohol (Martindale, 
2005). 5-ASA is a zwitterion with determined pKa values of 3.0, 6.0  and 13.9 (Allgayer et 
al., 1985). 
The 5-ASA is the active moiety of sulphasalazine (Williams and Hallett, 1989). For decades, 
this azo-compound has been a cornerstone in medical treatment of IBD, nevertheless, it is 
associated with a number of dose-dependent adverse events related to the sulphur in the 
sulphapyridine moiety (Nielsen, 1982; Shah and Peppercorn, 1995). Sulphasalazine combines 
an antibiotic sulphapyridine and an anti-inflammatory 5-ASA, and was originally developed 
by Nana Svartz in 1938 for possible use in rheumatoid arthritis (Svartz, 1948). The drug, 
however, proved to be effective primarily in the treatment of IBD (Das, 1983). In 1977, Azad 
Khan et al. studied a mechanism of action of sulphasalazine and discovered that 5-ASA is 
responsible for therapeutic effect. After, a rapid development in the field of new 5-ASA drug 
formulations with different principles of sustained release has taken place (Bondesen et al., 
1987; Wolf and Lashner, 2002). It has been pointed out that 80 % of patients intolerant to 
sulfasalazine will tolerate mesalazine without problems (D'Haens and van Bodegraven, 2004). 
The main goal of the treatment is to maximize delivery of 5-ASA to the affected regions of 
the colonic mucosa while minimizing systemic absorption which is related with adverse 
effects (Cohen, 2006). Mesalazine may cause headache and gastrointestinal disturbances, such 
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as nausea, diarrhoea, and abdominal pain. Hypersensitivity reactions may occasionally occur. 
There are some reports of pancreatitis and intersticial nephritis. Some patients may experience 
blood disorders including aplastic anaemia, thrombocytopenia, neutropenia, leucopenia and 
pancytopenia. It should not be given to patients with severe renal or hepatic impairment, or 
salicylate hypersensitivity (Martindale, 2005).  Following oral administration of conventional 
formulation, 5-ASA would be extensively absorbed from the upper GIT, with little of drug 
reaching the colon. Oral preparations are therefore generally formulated to release the drug in 
the terminal ileum and colon, where it is thought to exert a mainly local action. Absorption 
from rectal dosage forms is around 10 to 20 % of the dose. The absorbed portion of 
mesalazine is almost completely acetylated in the gut wall and in the liver to acetyl-5-ASA. 
The rate of acetylation, and hence the concentration of parent drug and metabolite in the 
systemic circulation, is dependent of the acetylator status. The acetylated metabolite is 
excreted mainly in urine by tubular secretion, together with traces of the parent compound. 
The elimination half-life of mesalazine is reported to be about 1 h and it is 40 to 50 % bound 
to plasma proteins. The acetylated metabolite has a half-life of up to 10 h and is about 80 % 
bound to plasma proteins (Klotz, 1985; Zhou et al., 1999; De Vos, 2000).  
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3.  CHITOSAN 
 
 
Fig. II.4: Chitosan structure (adapted from wikipedia) 
Molecular formula: (C6H12O4N)n      n ≈ 60-6060          Molar mass between 10 and 1000 kDa 
 
Chitosan is a cationic polymer derived from crustacean chitin, the second most abundant 
polymer in nature after cellulose (Roberts, 1992). Chitosan is a linear polysaccharide 
consisting of D-glucosamine and N-acetyl-D-glucosamine units (Kato et al., 2003). The 
degree of deacetylation of chitosan is usually between 70 and 95 % (Hamman, 2010). It 
occurs as white or creamy-white powder or flakes. Chitosan is sparingly soluble in water and 
practically insoluble in organic solvents, however, it dissolves slowly in acidic conditions. It 
gets precipitated and may look ‘cottonlike’ in alkaline solution, and forms gel at lower pH 
(Illum, 1998; Jones, 2009).  In the pH < pKa  (6.5), chitosan bears a positive charge and thus 
in turn reacts with many negatively charged surfaces/polymers. Indeed, mucoadhesive properties 
are due to molecular attractive forces formed by electrostatic interaction between positively 
charged amino groups of chitosan and negatively charged sialic acid residues of mucin resulting 
in potential retention of particles at the mucosal surface which can contribute to extended 
residence time in the target region (Smart, 2005; Shaikh et al., 2011). On the other hand, it 
spontaneously associates with negatively charged polyions in solution to form polyelectrolyte 
complexes useful for the design of different types of dosage forms (Hamman, 2010). Chitosan is 
digested by the enzymes produced by the colonic bacteria and thus is a favorable candidate for 
colonic-targeted drug delivery systems (McConnell et al., 2008). Chitosan as biocompatible, 
biodegradable and non-toxic material is suitable for use in a wide range of biomedical and 
pharmaceutical applications (Hirano et al., 1990). It has been extensively studied in wound 
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healing (Dai et al., 2011), as an antacid (Weisberg et al., 1966) and for hypocholesterolemic 
effects (Moon et al., 2007). Pharmaceutical applications are summarized in Table II.1. 
Table II.1: Pharmaceutical applications of chitosan 
Application References 
Diluent in direct compression of tablets Sawayanagi  et al., 1982; Mir et al., 2008 
Tablets and pellets disintegrant Ritthidy et al., 1994; Goyanes et al., 2011 
Binder in wet granulation 
Upadrashta  et al., 1992; Nunthanid et al., 
2004 
Drug carrier in hydrocolloids and gels Kristl  et al., 1993; Cheng et al., 2011 
Drug carrier in micro and nanoparticle 
systems 
Calija et al., 2012; Hosseinzadeh et al., 
2012 
Carrier in relation to vaccine delivery or 
gene therapy 
Chua et al., 2012; Klausner et al., 2012 
Hydrophilic matrix retarding drug release 
Säkkinen  et al., 2002; Wong and Nurulaini, 
2012 
Coating agent 
Mohamed et al., 2008; Sahasathian et al., 
2010 
Film-forming agent 
Fernandez-Saiz et al., 2009; Mengatto et al., 
2012 
Improvement of dissolution of poorly 
soluble drugs 
Portero et al., 1998; Maestrelli et al., 2011 
Absorption enhancer Sadeghi  et al., 2008; Rosenthal et al., 2012 
Viscosity increasing agent Felt et al., 1999; Perioli et al., 2008 
Mucoadhesive polymer He et al., 1998; Albertini et al., 2009 
Controlled drug delivery Di Colo et al., 2006; Yeh et al., 2011 
Site-specific drug delivery Keegan  et al., 2012; Mura et al., 2012 
Improved peptide delivery 
Dünnhaupt e al., 2012; Narayanan et al., 
2012 
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4.  SODIUM  ALGINATE 
 
 
Fig. II.5: Sodium alginate structure (downloaded from wikipedia) 
Molecular formula: (C6H7 Na O6)n       n ≈ 50-3000         Molar mass between 10 and 600 kDa 
 
Sodium alginate is obtained by neutralisation of alginic acid extracted from brown seaweed 
(Phaeophyceae). It contains α-L-guluronic and β-D-mannuronic acids in varying proportions 
and sequence (Draget, 2000). It is found as white to pale yellowish-brown colored powder 
which is slowly soluble in water, forming a viscous colloidal solution, and practically 
insoluble in ethanol (Cable, 2009). It is generally regarded as nontoxic and predominantly 
metabolized by colonic bacteria (Anderson et al., 1991; Matsubara et al., 1998). Gelation 
occurs by cross-linking of the uronic acids with divalent cations, such as calcium, strontium 
and barium ions, resulting in formation of three-dimensional network, which is usually 
described by egg-box model (Fig.II.6) (Grant et al., 1973). Moreover, it also can form a 
complex with the cationic polymer chitosan (Florczyk et al., 2011). Therapeutically, it has 
been used in combination with an H2-receptor antagonist in the management of 
gastroesophaegal reflux, as a hemostatic agent in surgical dressings and as a dressing to treat 
exhuding wounds (Qin and Gilding, 1996; Angspatt et al., 2010; Bordin et al., 2010). 
                 
Fig. II.6: Schematic representation of the egg-box structure (adapted from Rees, 1981) 
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Sodium alginate is widely utilized in cosmetics, food products, and variety of oral and topical 
pharmaceutical formulations. For instance, it has been used as a tablet binder and disintegrant 
(Sakr et al., 1978), as a diluent in capsule formulations (Veski and Marvola, 1993). It can 
delay the dissolution of a drug from tablets, capsules and aqueous suspensions, thus it is 
interesting in the preparation of sustained-release oral formulations (Zatz and Woodford, 
1987; Veski et al., 1994; Holte et al., 2003). In the same context, it plays a role of carrier in 
hydrophilic matrix controlled-release dosage forms (Sriamornsak and Sungthongjeen, 2007).  
It has been investigated for the aqueous microencapsulation of drugs (Chan et al., 2000) and it 
has also been studied in the formation of nanoparticles (Machado et al., 2012). In topical 
formulations, sodium alginate is widely used as a thickening and suspending agent in a 
variety of pastes, creams, and gels, and as stabilizing agent for oil-in-water emulsions (Cable, 
2009). Hydrogels, suspensions, oral mucosal, buccal and vaginal tablets, microspheres 
containing sodium alginate possess bioadhesive properties (Miyazaki et al., 1994; Vennat et 
al., 1998; Gavini et al., 2002; Mohammed and Khedr, 2003; Richardson et al., 2004; Gavini et 
al., 2005). In situ gel forming formulations for ophtalmic and oral-sustained drug delivery 
consisting of sodium alginate have been developed (Cohen et al., 1997; Kubo et al., 2003). 
Hydrogel systems containing alginates have been proposed for delivery of proteins and 
peptides (Jeon et al., 2011). In addition, sodium alginate microspheres for vaccine delivery 
have been explored (Mata et al., 2011). 
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III.  INFLAMMATORY  BOWEL  DISEASE 
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1.  GENERALITIES 
 
 Inflammatory bowel disease (IBD) comprises especially Crohn’s disease (CD) and 
ulcerative colitis (UC), which are defined as chronically relapsing immune-mediated 
inflammations of the gastrointestinal tract GIT over many years (Podolsky, 2002). Appearing 
initially as isolated cases in Great Britain and northern Europe during the 19th and early 20th 
centuries, they have steadily increased numerically and geographically and today are 
recognized worldwide (Kirsner, 2001).  
UC and CD are similar in many respects, but there are contrasting 
features. While CD is a multifocal, transmural inflammatory process 
which includes the presence of granulomas and fissures that can affect 
any part of the GIT (Fig. III.1), UC is characterized by a continuous, 
superficial inflammation, which occurs typically in the rectum and lower 
part of the colon with pseudopolyps as a frequent sequella (Fig. III.2) 
(Turnbough and Wilson, 2007; Atreya and Neurath, 2008).  
Fig. III.1: Inflammation in CD: It can appear along the entire GIT, but most commonly the 
ileum and colon are affected (downloaded from The bowel disease foundation) 
 
 
Fig. III.2: Differences in the localization and distribution of UC and CD with depiction 
of intestinal complications (adapted from Kumar et al., 2007) 
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In approximately 10 % of IBD, a definite diagnosis of UC or CD cannot be established 
due to either insufficient clinical data or prominent overlapping features between these two 
disorders. Under these circumstances, some pathologists choose to render a diagnosis of 
indeterminate colitis (Prenzel and Uhlig, 2009).  
IBD is a multifactorial disorder whose etiology remains unknown and furthermore the 
exact pathogenesis is poorly understood. Chronic, recurrent intestinal inflammation is thought 
to result from inappropriate and ongoing activation of the mucosal immune system driven by 
the products of commensal bacteria in the lumen. There is evidence of interactions among 
genetically determined susceptibility to chronic intestinal inflammation (gene encoding 
nucleotide-binding oligomerization domain containing 2 (NOD2), tumor necrosis factor 
(TNF), mucin, interleukin-10 (IL-10), etc.), the immune response (T cells, macrophages, 
active inflammatory cytokines), and the environment, most notably the bacterial flora, but 
also infection, use of nonsteroidal anti-inflammatory drugs, stress and smoking (in CD; 
protective role in UC) play an important role. The activation of immune system is eventually 
accompanied by the production of a wide variety of nonspecific mediators of inflammation. 
These enhance the inflammatory process and tissue destruction, which eventuate in clinical 
intestinal and extraintestinal manifestations of the disease. Clinical features of intestinal 
involvement include abdominal pain, rectal bleeding, nausea, diarrhoea, signs of malnutrition 
and weight loss. Patients complain of lassitude and recurrent fever. Extraintestinal features are 
common and represent ocular and dermal manifestations, hepatobiliary and renal disease, 
bone abnormalities and inflammatory seronegative arthropathies (Kirsner, 2001; Hendrickson 
et al., 2002; Podolsky, 2002).  
The frequency of IBD in industrialized countries contrasts with underdeveloped 
countries where disease rarely occurred. However, as these nations became industrialized, the 
incidence of UC and then CD increased (Kaplan et al., 2010). Moreover mechanisms 
underlying initiation vs. progression and chronicity may well be distinct (Elson et al., 1995). 
Hence, the treatment does not affect the cause of the illness and is effective only in reducing 
the inflammation and accompanying symptoms (Oz and Ebersole, 2008).  
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2.  ANATOMY  AND  HISTOLOGY  OF  BOWELS 
 
2.1.  SMALL  INTESTINE 
The small intestine, located within the abdominal cavity, is the longest section of the 
digestive tube and consists of three segments (duodenum, jejunum and ileum) forming a 
passage from the pyloric sphincter of the stomach to the ileocecal valve of the large intestine. 
Its average length in the human adult is 6 to 7 m (Rubin, 2009). The inner surface of the small 
intestine appears similar to velvet due to multiple circular mucosal folds known as plicae 
circulaires which are covered by millions of tiny projections, shaped like cactus leaves, 
called villi (Fig. III.3) extended about 1 mm into the lumen and with mature enterocytes on 
their surface. The lumenal plasma membrane of absorptive epithelial cells is studded with 
densely-packed microvilli looking something like a brush. For this reason, the microvillus 
border of intestinal epithelial cells is referred to as the "brush border". These three related 
features create the huge absorptive surface area of the small intestine (an area equivalent to a 
tennis court) (Gramlich and Petras, 2007).  
 
 
 
 
 
 
 
Fig. III.3: Bulk of the surface area expansion, showing villi (fingerlike and leaflike 
appearance), epithelial cells that cover the villi and the microvilli of the epithelial cells 
(adapted from Bowen, 2004)  
 
Crypts, moat-like invaginations of the epithelium around the villi, house a dynamic 
self-renewing population of undifferentiated multipotent stem epithelial cells generating 
mucus-secreting goblet cells, endocrine cells, mature absorptive epithelial cells fulfilling the 
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basic function of the digestive system and Paneth cells which probably play a role in 
regulating the intestinal microbial flora and provide defense against microbes by phagocytosis 
(Fig. III.4). From birth to death, intestinal epithelial cells live some 3 to 4 days, consequently, 
the turnover of intestinal epithelial cells is high. The crypt epithelium also contains 
intraepithelial lymphocytes that are predominantly T-suppressor/cytotoxic (cluster of 
differentiation 8+ (CD8+)) cells. Other inflammatory cell types, such as the neutrophil or the 
plasma cell, are not normally present within either the crypt or villous epithelial 
compartments and their presence would indicate a pathologic state (Bowen, 2004; Gramlich 
and Petras, 2007; Moran and Rowley). 
 
 
   
 
 
 
 
Fig. III.4: The four main differentiated cell types found in the epithelial lining of the 
small intestine (adapted from Alberts et al., 2002 (A); Gramlich and Petras, 2007 (B)) 
 
2.2.  LARGE  INTESTINE 
The large intestine constitutes the terminal part of the digestive system and is 
anatomically divided into three main sections: cecum including the vermiform appendix, 
colon (subclassified into ascending, transversal, descending, sigmoid), and terminal segment 
of digestive tube - rectum, continuous with the anal canal. In the adult, the large intestine 
measures approximately 1.5 m (Cohn et al., 2009). The large intestine looks very different 
from the small intestine. The surface of the mucosa is relatively smooth, because plicae 
circulares and intestinal villi are absent. On the other hand, microvilli are preserved and 
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greatly increase the surface area (Fig. III.5A). Crypts are usually deeper and straighter than 
those of the small intestine and mucus-secreting goblet cells are much more abundant in the 
colonic epithelium. Also the external appearance of the colon differs from that of the small 
bowel. Outer longitudinal muscle fibers coalesce into three discrete bands - teniae coli which 
start at the base of the appendix and extend continuously to the proximal rectum. Contraction 
of the teniae coli exerts pressure on the wall and creates a series of pouches, called haustra, 
along the colon (Fig. III.5B) (Dahl and Greenson, 2007; Moran and Rowley). 
 
 
 
 
 
 
Fig. III.5: Anatomy of large intestine (adapted from McPhee and Hammer, 2009 (A); 
Dorland, 2000 (B))  
 
2.3.  MICROSCOPIC  STRUCTURE  
Although regional differences exist within the GIT, the general microscopic structure 
is similar throughout its length. The wall of the digestive tube can be divided into four basic 
layers: mucosa, submucosa, muscularis externa or propria, and adventicia or serosa (Fig. 
III.6). Mucosa is the innermost layer of the digestive tube and lines the lumen. Among the 
four tunics, the mucosa is most variable in structure and function, endowing the tube with an 
ability to perform diverse and specialized digestive tasks along its length. The mucosa is 
formed by surface epithelium, lamina propria, and muscularis mucosae. The surface 
epithelium and lamina propria form intraluminal villi and/or crypts. Lamina propria contains a 
centrally located, blind-ended lymphatic channel (lacteal), an arteriovenous capillary network, 
and various types of leukocyte populations which control the inflammation. They include T 
cells, B cells, monocytes, macrophages, eosinofils and mast cells. Muscularis mucosae 
consists of a thin layer of smooth muscle at the boundary of the mucosa and submucosa. 
Submucosa is a bigger, tougher version of the lamina propria. It is a layer of loose to dense 
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fibrous connective tissue containing fibroblasts, mast cells, blood and lymphatic vessels, and 
nerve fiber plexus. Muscularis propria consists of two thick powerful layers of smooth 
muscles set in bidirectional orientations. Muscle fibers in the inner layer are aligned circularly 
and constrict the lumen, whereas those in the outer longitudinal layer shorten the tube. 
Together, as in a worm, they cause peristaltic movements and also provide the motive force 
for venous return of blood from the gut. A prominent nerve fiber plexus is found between 
these two muscle layers. The entire gut is wrapped in a collagenous bag, the serosa. When it 
covers retroperitoneal portions of the GIT, it is called adventicia (Geboes, 2003;  Bowen, 
2004; Gramlich and Petras, 2007). 
 
 
 
 
 
 
 
 
Fig. III.6: Microanatomy of the digestive tube. E, epithelium; IC, inner circular layer of 
muscularis externa; IG, intestinal glands; La, lacteal; LP, lamia propria; ME, muscularis 
externa; OL, outer longitudinal layer of muscularis externa; S, serosa; SUB, submucosa 
(adapted from Penn Medicine; Moran and Rowley) 
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3.  RELATED  BUT  DISTINCT  CHRONIC  INFLAMMATORY  DISORDERS 
 
Proper clinical separation UC and CD has important therapeutic implications. 
Accurate diagnosis often requires correlation of clinical, endoscopic and histopathological 
findings. The diagnostic work-up may also include hematological screening, renal and liver 
function tests, bile duct problems and inflammatory processes throughout the body. Although 
CD and UC each carry an increased risk of neoplastic transformation, the risk is higher and 
surgical intervention is better tolerated in UC (Hendrickson et al., 2002; Ricci et al., 2008; 
Rendi et al.). Irregular or villous surface, a decrease in mucus content and crypt atrophy is the 
best combination to distinguish UC. On the other hand, epitheloid granulomas, isolated giant 
cells and microgranulomas suggest a diagnostic of CD (Le Berre et al., 1995). The main 
features discriminating between the both diseases are seen in Fig. III.7 and described below.  
 
Fig. III.7: Colonoscopy pictures of colon in healthy (A), UC (B: wet and glaring mucosal 
surface with marked hyperemia) and CD patients (C: linear and serpinguous 
ulcerations and patchy inflammation resulting in cobblestone pattern) (adapted from 
Maxwell-Armstrong and Cohen, 2003 (A, B); Baumgart and Sandborn, 2007 (C)) 
 
3.1.  ULCERATIVE  COLITIS 
3.1.1.  History 
In all probability we shall never know who first described UC, although Sir Samuel 
Wilks first referred to the disease by name in 1859 (Hurst, 1923). Prior to that date, as far 
back as Roman times, various forms of non-contagious diarrhoea were described freely in the 
literature. The customary name of this disease “UC“ is  thoroughly imprecise, since ulceration 
A B C 
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is not a “sine qua non” of the disease and since the disease usually involves colonic and rectal 
mucosa. Undoubtedly “idiopathic diffuse mucosal proctocolitis” would be a more accurate 
descriptive term. The pathological and clinical features of the disease were closely 
characterized, notably by Wilks & Moxon (1875), Allchin (1885) and Hale-White (1888). 
Gradually UC became more widely recognized (De Dombal, 1968). Since then the disease 
has consistently increased in notoriety. Early in the 20th century, the incidence of UC was 
higher than CD. The number of individuals suffering from UC augmented steadily during the 
first half of the 20th century, after which the number has leveled out. Recent trends indicate a 
decrease in UC incidence. In the last decade, CD has become the predominating disease, with 
higher incidence rates than UC in most countries (Kaplan et al., 2010; Ekbom, 2011). 
 
3.1.2.  Epidemiology 
Figures from France and the Czech Republic show prevalence rates of 70-80 and 40-
45 per 100 000 population, respectively. Incidence rates vary between 7 and 4 per 1000 000 
population for France and the Czech Republic. All age groups are at risk, and the peak age of 
onset is between 30 and 40 years (Nerich et al., 2006; Hošek et al, 2008). UC has a slight 
male predilection (Karlinger et al., 2000). In clinical practice, UC is classified based on its 
severity being quiescent (remission), mild, moderate or severe attacks (Baumgart and 
Sandborn, 2007). Severe UC may progress in fulminant colitis and be complicated with toxic 
megacolon, and perforation (De Iorio, 2006). 
 
3.1.3.  Types  
 UC starts from the rectum, extends proximally and in continuity, involving a variable 
length of the colon (Fig. III.8). In ulcerative proctitis, the disease is confined to the rectum. In 
left-sided colitis or rectosigmoiditis, disease extends to the sigmoid colon. In pancolitis, the 
entire colon is affected, but normally inflammation stops abruptly at the ileocecal valve, 
nevertheless in some cases a limited distal ileitis, called backwash ileitis, is observed 
(Friedman and Blumberg, 2008). 
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Fig. III.8: Anatomic extent of UC involvement (adapted from Baumgart and Sandborn, 
2007) 
 
3.1.4.  Main features 
The general appearance of UC varies with the activity of the disease. Lesions are 
usually limited to the mucosa. Stenoses, fistulas, well-formed granulomas and significant 
thickening of the wall are rare. In the acute form, the mucosal surface is wet and glaring from 
blood and mucus with numerous petechial hemorrhages (Fig. III.9A). Ulcers of various sizes 
can appear. They may be small, rounded and superficial (rarely extend bellow the submucosa) 
or more irregular. Fissuring ulcers are not seen, except in some cases of toxic megacolon. 
Following healing of mucosal ulcers, islands of regenerating mucosa bulge upward to create 
pseudopolyps (elevated sessile reddish nodules, Fig. III.9B) which appear on an otherwise flat 
surface and covered by nonspecific granulation tissue. They are typically small and numerous, 
but may have a filiform configuration. In the more advanced stages, the entire bowel becomes 
fibrotic, narrowed, shortened, and mucosa is atrophic (Fig. III.9C). Mucosal abnormalities 
occurring in UC patients are also depicted in Fig. III.10. During remission, the mucosa may 
become normal again. Healing often occurs in an irregular way leading to a discontinuous, 
heterogeneous aspect of the mucosa, which can be confused with CD. In severe active forms 
the entire colon or a segment may become dilated (toxic megacolon). Inflammation may 
extend towards the submucosa. In such cases, the wall is thin and perforation can occur. 
Patients are in a high risk of carcinoma development (Geboes, 2003; Odze, 2003). 
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Fig. III.9: Main macroscopic features in UC: marked hyperemia (A), pseudopolyps (B), 
total mucosal atrophy (C) (adapted from Lockhart et al., 2004 (A, C); University of 
Michigan, Department of surgery (B) 
 
 
 
Fig. III.10: Spectrum of mucosal abnormalities in UC: punctate mucosal ulcer-crypt 
abscess (1), “collar button” ulcer (2), polypoid accumulation of granulation tissue (3), 
mucosal remnant forming inflammatory pseudopolyp (4), sessile mucosal polyps (5, 6), 
pedunculated polyp (7), postinflammatory pseudopolyps of various configurations (8, 9, 
10), mucosal remnant bridging area of active undermining ulceration (11), mucosal 
bridge in quiescent state with previously denuded surfaces covered with new epithelium 
(12) (adapted from Lichtenstein, 1987) 
 
 The microscopic pattern of UC is characterized by an increase in intensity of the 
lamina propria cellular infiltrate which extends diffusely towards the deeper parts 
(transmucosal distribution may be found). Chronic inflammation of the mucosa is 
accompanied with atrophy of colonic glands and moderate submucosal fibrosis however 
muscle wall is not usually affected (Fig. III.11A). The presence of neutrophils indicates a 
change in the composition of the inflammatory infiltrate. Accumulation of neutrophils within 
epithelial structures results in cryptitis (in the crypt wall) or abscesses (at base of the crypts) 
(Fig. III.11B,C), which are generally more common in UC, being present in 41 % of the cases 
while in CD they are found in 19 % of cases. Severe crypt architectural distortion, including 
A B C 
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shortened crypts that become widely separated from the underlying muscularis mucosae, 
crypt drop-out and especially prominent crypt budding (branching crypts, bifid crypts), is 
helpful feature for diagnosis of UC. Mucosal atrophy is a combination of crypt drop-out and 
their shortening. An irregular or villiform (reminiscent of small bowel mucosa) surface is 
present in approximately 60 % of patients. Blood vessels are dilated. Mucosal erosions and 
widespread surface epithelial damage are more common in UC that in CD. Severe, almost 
total mucin depletion occurs during the acute phase while mucin secretion returns to normal 
in quiescent phase. Abnormal mucin production may permit various intraluminal bacterial 
products and toxins to attack mucosa. (Cook and Dixon, 1973; Scott and Sanders, 1998; 
Geboes, 2003; Maxwell-Armstrong and Cohen, 2003). 
 
 
 
Fig. III.11: Histologic features in UC: inflammation of the mucosa, normal muscle wall 
(A), crypt abscess and glandular architectural distortion (B), crypt abscesses (C) 
(adapted from Glossary of pathology (A, B); Webster’s online dictionary (C)) 
 
3.2.  CROHN’S  DISEASE 
3.2.1.  History 
CD, originally called regional ileitis, takes its name from an American 
gastroenterologist B.B.Crohn. CD initially came to be known as a medical entity when it was 
reffered to B.B.Crohn and his colleagues, L. Ginzburg and G. Oppenheimer, in 1932 
(Blumberg, 2008). It is by virtue of alphabetization rather than contribution that Crohn’s 
name appeared as the first author. The first description of this condition was earlier made by 
physician G.B.Morgagni in 1769, when he diagnosed a young man with a chronic, 
debilitating illness and diarrhea. Successive cases of patients suffered from intestinal 
obstruction were reported in the end of 19th century. On close examination, transmural 
inflammation of the bowel wall was clearly evident. The early history of CD is probably also 
A B C 
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linked with the numerous reports of tumor-like granulomas of the small intestine, initially 
regarded as neoplastic lesions requiring surgical removal (Kirsner, 1988). Before 1950, 
incidence rates of CD were 0.2 in 100 000 population.  Afterwards, a rising incidence during 
the 1950s through to the 1980s was reported (Logan, 1998; Ekbom 2011).  
 
3.2.2.  Epidemiology 
The prevalence is 94-110 and 18-22 per 1000 000 population in France and the Czech 
Republic, respectively. The incidence of CD has significantly increased over the second half 
of 20th century and is higher in France than in the Czech Republic (6 versus 2 cases per 100 
000 people). The first peak of CD onset occurs in the teenage years, the second smaller peak 
during the fifth to seventh decades (Piront et al., 2003; Nerich et al., 2006; Hošek et al., 
2008). The condition is marginally more common in females (Podolsky, 2002). In clinical 
practice, disease activity is typically described as quiescent, mild to moderate, moderate to 
severe or severe to fulminant (Baumgart and Sandborn, 2007). Frequent complications 
associated with CD include bowel obstruction, fistulas and abscess formation (Knopp and 
Hokanson, 2006). 
 
3.2.3.  Classification  
CD most commonly affects the terminal ileum, ileocecal valve and cecum but has the 
potential to involve any part of the GIT. Based on the bowel segment it affects, CD has been 
classified into ileitis (only ileum), colitis (only colon) and ileocolic (involving ileum and 
colon) (Ruthruff, 2007). Pediatric patients with CD experience failure of linear growth, and 
delayed puberty caused by disease-induced malnutrition, poor appetite, or medical therapy 
(Tietjen et al., 2009).  
 
3.2.4.  Main features 
CD is characterized by a sharply delimited and transmural (full-thickness) 
inflammation of the bowel with mucosal damage (Fig. III.12A). The intestinal wall is rubbery 
and thick, due to oedema (mainly in submucosa), inflammation, fibrosis, and hypertrophy of 
the muscularis propria (Fig. III.12B). Oedema and fibrosis lead to splaying of the muscularis 
mucosae and distortion of the muscularis propria. The lumen is almost always narrowed, seen 
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radiographically as the "string sign". The length of the segments involved is variable and the 
lesions are separated by narrow areas of healthy tissue ("skip" lesions). The affected bowel is 
oedematous and ulcerated. Over a period of time, the erosions become confluent and give rise 
to larger longitudinal ulcers, known as serpiginous ulcers, which tend to be oriented along the 
axis of the bowel. The combination of longitudinal and transverse ulceration in an edematous 
mucosa induces a characteristic “cobblestone appearance” (Fig. III.12C). Chronic, trasmural 
inflammation can lead to deeply situated fissures reaching the muscularis propria or pass 
through the muscularis with ensuing abscesses or fistulas (tunnels) between involved 
segments and adjacent organs or nearby uninvolved loops (developed in almost 25 % of 
patients). Gut swells inwardly and stricures characterized by luminal narrowing and bowel 
wall thickening, can occur. Non-necrotizing granulomas composed of epithelioid histiocytes 
are commonly present. Especially single, long segment strictures are classic. Inflammatory 
pseudopolyps, tall mucosal outgrowths measuring a few milimeters in length, are often seen 
on the proximal side of an ulcerated stricture in approximately 20 % of the cases. The mucosa 
may appear normal or may show multiple small (1-2 mm in size) punctiforms, rounded 
nodules with white bases or superficial erosion known as “aphthoid ulcers”. Fat wrapping 
characterized by the overgrowth of mesenteric fat is observed in 75 % of the surgical 
specimens. Spectrum of radiologic changes occurred in patients with CD is shown in Fig. 
III.13 (Scott and Sanders, 1998; Maxwell-Armstrong and Cohen, 2003; Odze, 2003; Rendi et 
al.).  
 
 
Fig. III.12: Main features in CD: segmental involvement with transmural spread (A),                                                                                 
rigid thickening of bowel wall (B), cobblestone change of the mucosa (C) (adapted from 
University of connecticut health center (A); Rendi et al. (B, C)) 
A B C 
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Fig. III.13: Spectrum of radiologic changes in CD (adapted from Simpkins, 1988)  
 
The findings of granulomas in histological sections are a key feature of CD, although 
they may only be identified in 70 % of cases (Fig. III.14A). A granuloma is defined as a 
collection of monocyte/macrophages cells and other inflammatory cells (lymphocytes) with or 
without giant cells. They develop in all layers of the intestines from the mucosa to the serosa 
but are most frequent in the submucosa. The granuloma has to be distinguished from the 
microgranuloma, another important marker of CD which is smaller, composed of histiocytes 
and situated in the upper part of the mucosa. Early mucosal lesions, including epithelial 
patchy necrosis, the aphtoid ulcer or mucosal microulcerations, occur as focal lesions in a 
backround of normal mucosa in contrast with UC where diffuse epithelial necrosis is seen. 
The abnormalities of the enteric nervous system called neuromatous lesions are common and 
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most prominent in the submucosa. Inflammatory cell infiltration of blood vessels, obliterative 
lesions and lymphangiectasia (pathologic dilatation of lymph vessels) represent other 
distinguishing features of CD.  Lymphoid aggregates and nodules are found ordinarily in the 
mucosa and even more in the submucosa (Fig. III.14B). Deep fissures which extended into 
the muscularis propria are often observed (Fig. III.14C) (Kosugi et al., 2002; Geboes, 2003; 
Fefferman and Farrell, 2005).  
 
 
Fig. III.14: Histological features in CD: granuloma in the mucosa (A), lymphoid 
aggregate (B), prominent fissuring (C) (adapted from Rendi et al. (A, C); Dahl and 
Greenson, 2007 (B)) 
 
 
4.  IMMUNE  RESPONSE  AND  INFLAMMATORY  PATHWAYS 
 
Normal epithelium provides an effective barrier against luminal agents. The integrity 
of the barrier may be compromised by genetic variations, a diminished reparative response to 
injury, or exogenous agents, such as nonsteroidal anti-inflammatory drugs. Chronic, recurrent 
intestinal inflammation appears to result from stimulation of the mucosal immune system by 
penetrating products of commensal bacteria through the mucosal barrier, and subsequent 
promotion of a classic adaptive immune response. Alternatively, bacterial products may 
stimulate the surface epithelium through receptors and the epithelium can, in turn, produce 
cytokines and chemokines that recruit and activate mucosal immune cells (Podolsky, 2002). 
Elevated numbers of T cells in the mucosa affected by either form of IBD were detected. 
Type 1 helper T cells (Th1), secreting interferon-γ (INF-γ) and IL-2, are predominantly 
differentiated in patients with established CD. INF-γ leads to activation of macrophages, 
which in turn, produce IL-12, IL-18 and macrophage migration inhibitor factor and thus 
A B C 
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further stimulate Th1 in a self-sustaining cycle. Activated macrophages produce a potent mix 
of broadly active inflammatory cytokines, including tumor necrosis factor, IL-1 and IL-6. 
Conversely, atypical Th2 predominate in patients with UC and are characterized by the 
production of transforming growth factor ß, IL-5 and IL-13 (Fiocchi, 1998; Sands, 2000; 
Podolsky, 2002) (Fig.III.15). 
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Fig. III.15: Pathogenesis of IBD: antigen recognition and immunoregulation (adapted 
from Martins and Peppercorn, 2004; Cerf-Bensussan and Gaboriau-Routhiau, 2010) 
 
Concerning humoral immunity, an intestine with IBD shows a massive increase in the 
number of plasma cells with a 2, 5 and 30-fold increase in secretion of immunoglobulin 
(Ig)A, IgM and IgG, respectively. A selective enhancement of IgG1 synthesis was observed in 
UC, whereas IgG2 was accentuated in CD (Fiocchi, 1998). Patients with IBD possess a 
variety of circulating antibodies that may also help in detection of intestinal inflammation and 
differentiating CD from UC. A high prevalence of perinuclear antineutrophil cytoplasmic 
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antibodies was reported in patients with UC. Anti-Saccharomyces cerevisiae antibodies are 
frequently present in CD (Israeli et al., 2005). 
The activation of central immune-cell populations is eventually accompanied by the 
production of a wide variety of nonspecific mediators of inflammation including many other 
cytokines, chemokines and growth factors as well as metabolites of arachidonic acid (e.g., 
prostaglandins and leukotrienes) and reactive oxygen metabolites such as nitric oxide. 
Concentration of prostaglandin E2, tromboxane B2, leukotriene B4 and platelet-activating 
factor are markedly elevated in UC compared with CD and this may serve as a distinguishing 
diagnostic features. An inflamed gut of IBD patients is rich in activated macrophages and 
neutrophils and these inflammatory cells generate excess amounts of reactive oxygen species 
with subsequent increase in oxidative stress. Moreover intestinal mucosa is relatively depleted 
of antioxidant defenses, rendering it more susceptible and contributing to intestinal oxidative 
injury. All these mentioned mediators enhance the inflammatory process itself and tissue 
destruction, which eventuate in the clinical manifestations of the disease (Conner et al., 1996; 
Yang, 1996; Pavlick et al., 2002; Oz and Ebersole, 2008).  
 
 
5.  MEDICAL  MANAGEMENT  
 
IBD presents a problem in public health because of its high incidence in early 
adulthood and its chronic clinical course. IBD remains largely incurable and commonly 
requires a lifetime of care. Although not particularly a cause for mortality, IBD is associated 
with significant morbidity and decreased quality of life is not negligible (Fatahzadeh, 2009; 
Turnbough and Wilson, 2007). Current drug medication aims to induce and then maintain the 
patient in remission and ameliorate the disease’s secondary effects (Harris et al., 2009). 
Therapy is individualized, requires time to work, and is often associated with side effects 
(Fatahzadeh, 2009).  Table III.1 provides a summary of current medical therapy for IBD in 
France and in the Czech Republic. Routine treatment has not changed significantly over the 
last 40 years and still relies mostly on anti-inflammatory drugs, such as aminosalicylates and 
corticosteroids (prednisone, prednisolone, budesonide, etc.). In severe disease or in patients 
who fail conventional therapy immunosuppresive (azathioprine, 6-mercaptopurine, 
methotrexate, cyclosporine) and biologic agents (infliximab, adalimumab, certolizumab 
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pegol) are applied (Kozuch and Hanauer, 2008). Antibiotics (metronidazole, ciprofloxacin) 
are useful in the treatment of subgroups of patients with CD (Lal and Steinhart, 2006).  
Table III.1: Commercialized drugs for the treatment of IBD (adapted from Vidal® 2012; 
Kašparová et al., 2012) 
* O - orally, R - rectally, IV - intravenously, SUB - subcutaneously 
 
 
Drug Brade name 
in France in the Czech Republic 
Aminosalicylates 
Sulfasalazine Salazopyrine - O* Salazopyrin - O 
Sulfasalazin - O 
Olsalazine Dipentum - O -  
Mesalazine Fivasa - O, R*  
Pentasa - O, R 
Rowasa - O, R 
Asacol - O, R 
Pentasa - O, R  
Salofalk - O, R 
Corticosteroids 
Prednisone Cortancyl - O Prednison - O 
Prednisolone Solupred - O - 
Methylprednisolone Médrol - O Depo-medrol - IV* 
Solu-medrol - IV 
Medrol - O 
Hydrocortisone Colofoam - R - 
Budesonide Entocort - O 
Rafton - O 
Budenofalk - O 
Entocort - O, R 
Betamethasone Célestène - O 
Betnesol - R 
Diprophos - R 
Immunosuppressive drugs 
Azathioprine Imurel - O Immunoprin - O 
Biological agents 
Infliximab Remicade - IV Remicade - IV 
Adalimumab Humira - SUB* Hunmira - SUB 
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Advances in the understanding of the pathophysiology of IBD, have led to the 
development of several new treatment strategies which selectively inhibit crucial mediators of 
the inflammatory process and target specific biomolecules such as human recombinant 
cytokines IL-10, 11; monoclonal antibodies against IL-12, TNF-α and INF-γ; recombinant 
growth factors, p38 antagonist, nuclear factor-kappa B (NF-κB) with many more on horizon 
that may well provide future alternative therapy. Effective antioxidant therapies could be 
another interesting possibility of treatment because free radicals may be responsible for a 
great deal of direct injury to the mucosa and may account for increased cancer risk (Sands, 
2000; Triantafillidis et al., 2011). 
 
5.1.  CURRENT  THERAPIES 
5.1.1.  5-aminosalicylates 
 The 5-aminosalicylate based compounds have remained cornerstone of the treatment 
for patients with mild to moderately active UC and CD since the recognition of the 
therapeutic efficacy of the prototypical agent sulfasalazine in 1940. Maintenance treatment 
with 5-aminosalicylate formulations can be effective for sustaining remission induced by 5-
aminosalicylates in mild to moderate UC or corticosteroids in severe UC, but is of 
questionable value in CD. Finally, long term use of 5-aminosalicylate in UC may decrease 
colorectal cancer risk by 50 %. Their exact mechanism of action is still not fully understood. 
5-aminosalicylate may act by blocking the production of prostaglandins and leukotrienes, 
inhibiting bacterial peptide-induced neutrophil chemotaxis and adenosine-induced secretion, 
scavenging reactive oxygen metabolites, and perhaps inhibiting the activation of nuclear 
factor-κB. In general, pharmaceutical forms should be selected principally on the basis of 
disease location. Proctitis and left-sided UC might respond better to rectal formulations such 
as suppositories, enemas or foams. Oral prodrug formulations (sulfasalazine, olsalazine and 
balsalazide), in which 5-aminosalicylic acid (mesalazine) is conjugated to prevent absorption 
by the small bowel, are appropriate for colonic disease. Mesalazine delayed-release 
formulations based on ethylcellulose (time-dependent release) or methacrylic acid copolymers 
(pH-dependent concept) can deliver therapeutic concentrations to the more proximal small 
bowel or distal ileum to expand the spectrum of patients with CD. Up to 30 % of patients 
taking sulfasalazine are intolerant and newer 5-aminosalicylate oral formulations avoiding 
adverse effects principally related to sulfapyridine moiety are useful for treatment. Newer 
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formulations also reduce pill size and could be taken only once per day which increases 
patients compliance (Sands 2000; Podolsky, 2002; Cohen 2006; Baumgart and Sandborn, 
2007; Harris et al., 2009; Triantafillidis et al., 2011). The available mesalazine formulations 
are described in detail in review article Bautzová et al. (2011).  
 
5.1.2.  Corticosteroids 
Corticosteroids have been used for over 50 years to treat IBD. Oral corticosteroids are 
efficacious in decreasing disease activity and inducing remission in most IBD patients not 
respondent to aminosalicylates or with severe disease activity.  They are not recommended for 
maintenance therapy due to numerous undesirable side effects and not proven benefit. Some 
patients could become steroid-dependent or steroid resistant. Budesonide, as an enema or a 
controlled-ileal release formulation, provides markedly reduced side-effects of systemic 
corticosteroids and hence is ideal for inducing and prolonging remission in mild to moderate 
CD involving distal ileum and proximal colon. Topical preparations including enemas and 
foam may reduce symptoms in patients with proctitis and limited distal UC. Intravenous 
corticosteroids are applied in fulminant UC patients with significant abdominal cramping, 
bloody diarrhea and abdominal tenderness until symptoms subside. Corticosteroids diminish 
production of a host proinflammatory cytokines, directly inhibit a variety of leukocytes 
functions and interfere with metabolism of arachidonic acid causing an alteration in the 
delicate balance between the cytoprotective prostaglandins and proinflammatory leukotrienes 
(Sands, 2000; Hendrickson et al., 2002; Kozuch and Hanauer, 2008). 
 
5.1.3.  Immunosuppressive and immunoregulatory agents 
Immunomodulators such as 6-mercaptopurine or its prodrug azathioprine are purine 
analogs that interfere with nucleic acid synthesis and thereby exerting an antiproliferative 
effect on mitotically active lymphocyte populations. Widespread use of immunosuppressives 
agents is minimized due to severe adverse effects (Hendrickson et al., 2002; Baumgart and 
Sandborn, 2007). Nevertheless, they are suitable for patients with steroid dependency and 
those who are unresponsive to 5-aminosalicylate or corticosteroid therapy to avoid long term 
use of corticosteroids. They are slow-acting, steroid-sparing agents best suited for 
maintenance rather than inductive therapy in IBD. Azathioprine and/or 6-mercaptopurine can 
also form the basis in of chronic therapy for extensive small bowel disease and as a second-
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line treatment of fistulizing CD, for which both aminosalicylates and steroids are ineffective. 
It must be stressed that the majority of patients relapse when azathioprine and 6-
mercaptopurine are withdrawn (Fraser et al., 2002; Hendrickson et al., 2002; Kozuch and 
Hanauer, 2008). Methotrexate is appropriate for the treatment of steroid-dependent or steroid 
refractory chronically active CD and for maintaining long-term remission. It has not proven 
effective in patients with UC. Methotrexate, as a folate analog, influences impaired 
deoxyribonucleic acid (DNA) synthesis, decreases expression of IL-1 and induces apoptosis 
and must be administered in conjuction with folic acid (Podolsky, 2002; Wolf and Lashner, 
2002; Harris et al., 2009). Cyclosporine, a lipophilic cyclic polypeptide, is adequate for 
patients with acute steroid-refractory severe UC in a last attempt to prevent proctocolectomy. 
In general, it should not be used in the treatment of CD, with the possible exception of 
patients with symptomatic and severe perianal or cutaneous fistulas. By inhibiting 
proinflammatory transcription factors, cyclosporine diminishes cytokine production and 
exerts an antiproliferative effect on lymphocytes (Sands, 2000; Harris et al., 2009). 
Tacrolimus is a calcineurin inhibitor that suppresses proinflammatory cytokine production 
and T-cell activation. Tacrolimus is adequate for the patients with fistulising CD and 
refractory UC (Triantafillidis et al., 2011).  
 
5.1.4.  Biological agents 
 Tumor necrosis factor alfa, a product of activated macrophages and a powerful 
proinflammatory cytokine, plays a pivotal role in the process of the inflammation in IBD 
patients. Inhibition of this cytokine is expected to be a powerful treatment strategy in patients 
with both UC and CD. Moreover, anti-TNF-α therapy is a strong inducer of mucosal healing 
(Pallone and Monteleone, 2001; Triantafillidis et al., 2011). Infliximab (a chimeric mouse-
human monoclonal IgG1 antibody) or its alternatives as adalimumab (a recombinant fully 
human monoclonal IgG1 antibody) and certolizumab pergol (an antigen-binding fragment 
portion of IgG antibody attached to polyethylene glycol) are beneficial in control of 
overactive inflammatory process. They have efficacy in induction and maintenance therapy in 
moderate to severe UC and CD in patients failing or poor tolerating conventional therapies. 
They have been successfully used as well as for the treatment of fistulas in patients with CD. 
Adalimumab appears to be a beneficial option for IBD patients who cannot tolerate infliximab 
or are symptomatic despite receiving infliximab therapy. These agents bind circulating and 
membrane-bound TNF-α, induce a cell mediated cytotoxic reaction and enhance the 
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programmed cell death of activated T-cells monocyte (Podolsky, 2002; Baumgart and 
Sandborn, 2007; Triantafillidis et al., 2011). Thalidomide, anti TNF-α antibody blocking the 
production of TNF-α, inhibiting the formation of superoxide and hydroxyl radicals and 
stabilizing lysosomal membranes, was found to be efficacious in patients with chronically 
active, steroid-dependent CD (Evans, 2000;  Ginsburg et al., 2001). Although highly 
effective, these agents are expensive and associated with serious adverse effects, related with 
powerful immunosuppressive capacity, mandating careful patient selection, counseling and 
close follow-up (Ricci et al., 2008; Fatahzadeh, 2009). 
 
5.1.5.  Antibiotics 
The rationale for using antibiotics is based on the assumption that intestinal bacteria 
are involved in the pathogenesis of the disease. Enteric flora is altered and immunological 
tolerance to commensal bacteria has been lost in patients with IBD. Antibiotic therapy with 
metronidazole or ciprofloxacin, possessing also innate immunomodulatory activity, is widely 
used for the first-line treatment of perianal fistulas in CD and is effective in treating mild to 
moderate CD. In contrast, antibiotics have very limited use in UC except for hospitalized 
patients with fulminant colitis at risk for sepsis. Metronidazole ointment could be used as 
potential treatment for pain and discharge associated with perianal CD with minimal adverse 
effects. Ornidazole, clarithromycin and rifaximin have been shown efficacious in inducing 
clinical remission in active CD. The antibiotics treatment is associated with important adverse 
effects and a risk for Clostridium difficile infection (Podolsky, 2002; Baumgart and Sandborn, 
2007; Kozuch and Hanauer, 2008; Triantafillidis et al., 2011). 
 
5.1.6.  Probiotics 
Probiotics are live non-pathogenic microorganisms that improve microbial balance in 
the GIT through various mechanisms, including reduced intestinal pH, decreased colonization 
and invasion by pathogenic organisms, and modification of the host immune response. They 
consist of Saccharomyces boulardii, Lactobacillus and Bifidobacterium spp. Use of probiotics 
appears to be one promising approach free of systemic side effects in achieving clinical 
response and remissions in patients with mild-to-moderately active distal UC and pouchitis in 
CD patients (Podolsky, 2002; Triantafillidis et al., 2011). 
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5.1.7.  OTC and diet 
Patients afflicted with IBD may also benefit from taking over-the-counter antidiarrheal 
agents (codeine, diphenoxylate, loperamide), laxatives and pain medications for palliation of 
intestinal symptoms. Although there is little support for a dietary factor in triggering IBD, 
modifications in the diet (restriction of high-fiber, spicy food, uncooked vegetables and nuts) 
and lifestyle may also help with bowel syndromes (Evans, 2000).  
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As IBD primarily represents a local inflammation of the mucosa in the colon and in 
parts of the small bowel, it would be ideal to target the therapeutic principles directly to the 
affected areas. Topical administration of the drug in form of enemas, foams, gels or 
suppositories seems to be more effective since the colon or rectosigmoid area are affected. 
However, patients often dislike rectal formulations. Nowadays, oral delivery represents the 
most common and preferred route of drug administration. The optimal dosage schedule for 5-
ASA range from 2 to 4 g/day which lead to the multiple tablets intake several time a day and 
lack of patient compliance. Thus multiparticulate dosage forms were introduced to overcome 
the disadvantages of single unit dosage forms. The main aim of this work was to design 
multiparticulate system, e.g. pellets in our case, for colon-specific drug delivery intended for 
the treatment of IBD. It was demonstrated that the pellets are less influenced with diarrhoea in 
IBD patients and promising in order to reduce the dosage frequency.  
Since, IBD affects approximately one in five hundred inhabitants in the Western world 
and conventional treatment is usually related with more or less serious adverse effects, the 
first objective of our study was to design multiparticulate system based only on natural 
substances and efficient in reducing inflammation process. In several in vivo studies, rutin, 
one of the most common naturally occurring flavonoids possessing anti-inflammatory and 
antioxidant properties, has shown the therapeutic benefit in experimental colitis. The major 
goal was to identify novel polymeric film coatings for chitosan-core pellets based on natural 
polysaccharides degraded by colonic microbiota, protecting pellets from the disintegration in 
the acidic environment of the stomach, allowing for the site-specific delivery of the rutin to 
the colon and ensuring increased local drug concentration in the site of the inflammation. For 
this purpose, different types of polymer coatings have been investigated. It was expected that 
rutin loaded pellets will provide significant mitigating effect in experimental colitis 
comparable to marketed 5-ASA pellets avoiding side effects related to commonly used 
treatment and thus could be a promising approach in therapeutic strategy in IBD. 
Aminosalicylates belong to the current first-line treatment for mild to moderate IBD 
which are used to treat active symptoms and to maintain periods of remissions. Two different 
therapeutic approaches have been employed to target the active 5-ASA to its site of action and 
to avoid possible adverse effects related with its absorption in the upper intestine. Either 
inactive azo-prodrugs or special galenic formulations coated with the pH-dependent polymers 
or semi-permeable membrane have been developed. Nevertheless, for the present bioadhesive 
formulations able to increase drug concentration in the site of pathology have not been 
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marketed yet. The second objective of the thesis was to prepared 5-ASA loaded pellets with 
pH dependent coating containing chitosan, a biodegradable polymer with bioadhesive 
properties, in their core to ensure longer residence time of multiparticulate system in the 
target region. It was supposed that this approach will result in lower systemic drug 
bioavailability, augmented mucosal drug concentration in the colonic tissue and better 
therapeutic effect.   
All pellets were prepared by E/S method and subsequently coated in the fluidized bed 
coater. Dissolution studies at different pH levels were conducted throughout the study and 
anti-inflammatory effect of pellets was evaluated in vivo in trinitrobenzene sulfonic acid 
(TNBS)-induced colitis in rats. Also, plasma pharmacokinetic studies provided data on 
systemic exposure that might be one determinant of side effects, but not on colonic 
distribution or mucosal uptake was carried out. In addition, biodistribution of N-acetyl-5-ASA 
in GIT tissues predicted therapeutic efficacy which depends on local drug concentration in the 
colonic mucosa was assessed. For reasons of comparison, drug release, anti-inflammatory 
activity and pharmacokinetic parameters of commercially available product was determined. 
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1.  PREPARATION  OF  PELLETS 
 
The pelletization process consists of the agglomeration of fine powders of active drug 
and excipients into small spherical units of acceptable size and size distribution (Ghebre-
Sellassie, 1989). Among existing pelletization techniques, E/S represents an established and 
the most popular method used to produce pharmaceutical pellets (Charoenthai et al., 2007a). 
In general, this process consists of the compaction of a wet powder mass leading to an 
intermediate spaghetti-like product, which is promptly spheronised obtaining a final spherical 
product (Santos et al., 2002). E/S is advantageous method for preparing high drug loading 
pellets of uniform size and good mechanical properties, but it is time consuming process of 
several steps (Vervaet et al., 1995; Charoenthai et al., 2007a).  
Successful production of pellets by E/S requires the addition of the excipients to aid 
rheological suitability, i.e. plasticity, rigidity, water absorbing capacity and cohesiveness, of 
the wet powder mass. To dates, microcrystalline cellulose (MCC) is regarded as the essential 
excipient to obtain spherical pellets with low friability, high density and smooth surface 
properties (Charoenthai et al., 2007b). MCC has good binding properties and provides 
cohesiveness to the wet mass (Dukić-Ott et al., 2009). Furthermore, MCC, acting as a 
molecular sponge, is able to hold large amounts of freely mobile water in the wet stage, 
confers the appropriate degree of plasticity to the wet mass, controls the movement of water 
through this mass during extrusion and enhances spheronisation (Lustig-Gustafsson et al., 
1999; Di Pretoro et al., 2010). In the last decade, the use of chitosan in mixtures with MCC 
for the production of pellets via E/S has been reported by several authors (Santos et al., 2002; 
Steckel and Mindermann-Nogly, 2004; Charoenthai et al., 2007a). Chitosan, likewise MCC, 
can act as a molecular sponge (Agrawal et al., 2004). Moreover, this natural polysaccharide is 
readily degraded by bacteria in the colon, which makes it interesting for colon-specific drug 
delivery systems (Zhang and Neau, 2002). Recently, Charoenthai et al. (2007a) have 
demonstrated that pellets produced by E/S with low (190 kDa) instead of high (419 kDa) 
molecular weight chitosan possess higher mean diameter, sphericity, and crushing force. 
Taking into account all the above considerations, MCC and low molecular weight chitosan 
(162 kDa) was used for pellets preparation in our experiment.  
Apart from excipients, the moisture of the granulated mass is an extremely important 
formulation parameter in the E/S process regarding the shape and the size of produced pellets. 
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Two extremes can be recognized. Moisture content exceeding the optimum quantity leads to 
an overwetted mass and agglomeration of the pellets during spheronisation due to the excess 
of water at the surface of the pellets. While a lower limit exists where the wet mass is too dry, 
resulting in a generation of cylindrical or non-rounded pellets with a lot of quantity of dust 
(Charoenthai et al., 2007b). Previous works imply that the amount of liquid necessary to 
obtain a wet mass with the required plasticity is highly dependent on the physical and 
chemical properties of the active pharmaceutical ingredient and excipients, such as solubility, 
particle size and morphology, specific surface area and packing behavior (Lustig-Gustafsson 
et al., 1999; Di Pretoro et al., 2010). Thus, less amount of wetting liquid is needed to produce 
appropriate extrusion mass in powders containing larger particles of sparingly soluble 
substances than in fine powders. Furthermore, the amount of liquid is reduced with increasing 
solubility of the drug and/ or excipients (Krejčová et al., 2006). Therefore, particle size 
characterization was performed using an optical microscope fitted with a camera and 
computer for automatic image analysis to estimate the amount of liquid necessary to produce 
the extrudate and minimize inadequate number of experiments. 
In general, water is the most often used granulation liquid in E/S (Vervaet et al., 
1995). The results of Steckel and Mindermann-Nogly (2004) have indicated a successful 
extrusion of chitosan and MCC in a maximum ratio of 1 to 1 using water. Whereas, replacing 
the water by a 0.1 N (0.6%) acetic acid solution enabled the production of pellets with a 
chitosan content of up to 70 % due to partial dissolution of chitosan giving sufficient plastic 
formability to the wet mass. Additionally, previous work in our laboratory focused on 
preparation of chitosan matrix pellets (Janovská et al., 2009) revealed that 0.25% acetic acid 
is ideal for production spherical pellets which led us to employ this solution as granulation 
fluid in present experiment. In fact, the optimal amount of binding liquid was evaluated 
experimentally in order to achieve acceptable sphericity and required size distribution. It is 
interesting to note that it was possible to produce spherical pellets when water was added as 
wetting agent however this formulation showed faster drug release in phosphate buffers of pH 
3.0 and 6.8, respectively (Fig. IV.1). On the other hand, drug release rate decreased when dry 
powder mixture was wetted with acetic acid. It might be speculated that partially dissolved 
chitosan facilitates viscous gel layer formation controlling drug release.  
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Fig. IV.1: Drug released profiles from uncoated rutin pellets in phosphate buffer of pH 
3.0 (diamond) or pH 6.8 (triangle). The plastic masses were wetted with water (empty 
symbols) or diluted acetic acid (full symbols). Data are shown as mean ± SD. 
 
 
2.  EVALUATION  OF  PELLETS 
  
As seen in Fig. IV.2, pellet size distribution determined prior to the coating process 
showed three main fractions for 5-ASA pellets as well as for rutin pellets. Main pellets 
characteristics were evaluated and are summarized in Table IV.1. Both pellet samples 
presented high drug content and suitable sphericity higher than critical value of 0.80 (Deasy 
and Law, 1997). Pellets showed good mechanical properties, i.e. pellet hardness and friability, 
what is typical for extrusion/ spheronization method (Häring et al., 2008). Mean diameter of 
rutin pellets was bigger than that one of 5-ASA pellets; then pellet fraction of 0.5-1.0 mm was 
used for the following coating process.  
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Fig. IV.2: Pellet size distribution in the fractions determined by sieve analysis  
 
Table IV.1: Pellet characteristics 
Pellets 5-ASA Rutin 
Drug content [%] 94.6 ± 1.4 94.6 ± 1.4 
Mean diameter [mm] 0.62 0.89 
Sphericity 0.8335 ± 0.03 0.8295 ± 0.04 
Hardness [N] 10.2 ± 1.7 10.8 ± 1.1 
Friability [%] 0.053 ± 0.02 0.051 ± 0.01 
 
 
3.  COATING  OF  PELLETS 
 
In the pharmacotherapy of IBD, colon-specific drug delivery systems represent an 
interesting approach since they prevent drug release in the stomach and small intestine, and 
provide an abrupt onset of drug release upon entry into the colon (Yang et al., 2002). In order 
to obtain required controlled release effect and achieve colon specific drug delivery which can 
significantly improve the efficacy of local treatments of IBD as well as lower distinct adverse 
effects, different polymers have been investigated. Film coatings with pH-dependent 
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properties, most commonly based on methacrylic acid copolymers marketed under the trade 
name Eudragit®, substituted polyvinyl acetate or some cellulose derivates, are well 
established and commonly used during the past decades (Kietzmann et al., 2010). Besides, 
ethylcellulose membranes may be applied in order to achieve prolonged drug release in the 
cases when CD occurs also in upper GIT (Bautzová et al., 2011). Taking into consideration 
the variations in intestinal and colonic pH, gastrointestinal motility and inherent variability in 
gastrointestinal transit times in patients with IBD, pH- and time-dependent systems seem to 
be less reliable and site-specificity of drug release more unpredictable (Nugent et al., 2001; 
McConnell et al., 2008b). It is noteworthy to mention that over 500 distinct species of bacteria 
with a population of 1011-1013 CFU/ml, greatly outnumbering microbiotal colonization in the 
upper parts of GIT, reside in the large intestine and this microbiota is increasingly recognized 
as a preferable triggering component in the design of colon-specific drug delivery systems 
(Sousa et al., 2008). In this context, naturally occurring polysaccharides, stable in the upper 
intestine, but susceptible to hydrolytic degradation by the colonic microbiota, have arisen as 
an ideal candidate material for enzyme-based systems (McConnell et al., 2008b). In our 
experiment microbially degradable coating of rutin pellets and pH-dependent coating on the 
surface of 5-ASA pellets were compared. Both samples contained chitosan in the pellet core. 
Degradable coating was composed of alginate and chitosan, polysaccharides of natural origin. 
Chitosan, a cationic polymer should interact with anionic polymer alginate and form water 
insoluble barrier, which influences the release of drug prior to pellet arrival in the colon where 
the both undergo microbial degradation and thus ensure colon drug delivery (Mitrevej et al., 
2001). In order to prevent 5-ASA release in the upper GIT, Eudragit FS (EFS) was chosen for 
5-ASA pellets. EFS dissolves at pH equal or higher than 7 (Potestà, 2001), i.e. this coating 
can be partially dissolved - depending on the coating thickness - under proximal ileum 
conditions. pH values differ significantly within the distal gut showing the values of 2.3-7.2. 
In alkaline pH, EFS coating will dissolve releasing the drug. If pH value would decrease to 
acidic values in the colon, chitosan in the core will dissolve and help the drug to release 
through the fissures or pores formed in the coating in previous alkaline environment 
(Rabišková et al., 2012). 
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4.  DISSOLUTION  TESTING 
  
In vitro dissolution testing takes an important role in the development of solid dosage 
forms, especially those with controlled release, and should be conducted under conditions 
simulating demanded GIT  environment (Yang et al., 2002).  
First, conventional dissolution method was applied for assessing the ability of coated 
pellets to prevent drug release in the stomach and small intestine. Dissolution profiles of 
uncoated and coated pellets were determined in 0.1N hydrochloric acid (HCl) (5-ASA and 
rutin pellets) or phosphate buffer of pH 3.0 (rutin pellets) simulating gastric conditions in 
fasted and fed state in man (McConnell et al., 2008a). Preliminary dissolution tests were 
carried out also in phosphate buffer of pH 6.8 mimicking conditions in the small intestine 
(Shimono et al., 2003). At pH 1.2 (Fig. IV.3A), uncoated pellets release both drugs quite fast: 
immediate 5-ASA release compared to rapid rutin release is probably related to 40 fold higher 
solubility of 5-ASA at pH 1.2 (French and Mauger, 1993, for rutin determined 
experimentally). Additionally, rutin release rate at pH 3.0 decreased due to lower solubility of 
rutin in this medium. Applied coating, either EFS for 5-ASA pellets or alginate/chitosan (AC) 
for rutin pellets, minimized significantly drug release from the formulations. Coating of 5-
ASA pellets is acidoresistant and therefore minimum drug release was observed. AC coated 
pellets exhibited different rutin dissolution profile in differing acidic media: approximately 
14.8 ± 2.5 % of the drug was released at pH 3 at the end of dissolution testing, while 
significant rutin amount was released in the first hour of the testing at pH 1.2. According to 
the observations of Elzatahry et al. (2009), it might be speculated that at pH 3.0 the formed 
polyelectrolyte complex between carboxyl residues of alginate and amino groups of chitosan 
is denser resulting in lower drug release. As is evident from the dissolution profiles in 
simulated gastric conditions, an additional outer enteric coating is necessary to prevent drug 
release from the chitosan-core pellets intended for colon-specific drug delivery. At pH 6.8 
(Fig. IV.3B), the higher 5-ASA solubility compared to rutin contributed to the faster drug 
release from uncoated pellets. Rutin release from uncoated pellets in simulated intestinal fluid 
is hindered by insoluble chitosan matrix at this pH, while in the body chitosan is decomposed 
by intestinal microbiota (Zambito and Di Colo, 2003; McConnell et al., 2008c). Slow release 
of 5-ASA from coated pellets was expected as EFS dissolves at pH=7 and higher (Potestà, 
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2001). Also rutin release from coated pellets was very slow due to insoluble chitosan matrix 
and AC coating which in vivo are decomposed in the colon (Jain et al., 2007).   
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Fig. IV.3: Drug released profiles from uncoated (full symbols) and coated (empty 
symbols) rutin (♦)  and 5-ASA (▲) pellets in 0.1N HCl and rutin (●)  in phosphate 
buffer of pH 3.0 (A); and phosphate buffer of pH 6.8 (B). Data are shown as mean ± SD. 
 
For in vitro evaluation of colon-specific drug delivery systems, the dissolution testing 
should closely mimic the in vivo conditions. Hence, a continuous dissolution method in 
buffers of different pH and reflecting residence time was performed in order to simulate 
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transit of pellets through the GIT. It was demonstrated that upper parts of GIT are hardly 
influenced by disease state of IBD (Press et al, 1998) and intraluminal pHs showed a similar 
pH values in proximal (6.1-7.3) and distal small bowel (6.8-8.3). Nonetheless, large pH 
variability in the caecum and right colon has been reported (2.3-7.3) (Nugent et al., 2001).  
Time profile of release tests was based on data of Davis et al. (1986) indicating the average 
gastric emptying time of 2 h and small intestinal transit time of approximately 3 h after oral 
administration of pellets in healthy humans. Additionally, previous work implies that overall 
transit time in the disease state is similar to that found in healthy volunteers although transit 
through the proximal colon is on average slower while accelerated transit through the 
rectosigmoid region was observed (Davis et al., 1991). Similarly, experimental colitis had no 
effect on the intestinal transit (De Schepper et al., 2007). According to the literature, no 
differences were detected in transit profiles of pellets between human and rats (Mori et al., 
1989). In fact, release characteristics of coated pellets were examined by four sequential 
dissolution media with different pH values in order to mimic pH changes along GIT (Fig. 
IV.4). Dissolution profiles of both drugs are similar indicating insignificant drug release under 
the upper GIT conditions and fast drug release in the media mimicking distal GIT parts. Being 
acidoresistant, EFS coating prevented drug release at pH 3.0 and showed minimum drug 
release at pH 6.8. 5-ASA release was fast after the exposure of EFS coated pellets to pH 7.5 
for 30 min. and this trend continued even in the medium of pH 4.0. Rapid drug release 
through EFS coating was ensured by the supporting effect of dissolved chitosan from the 
pellet core and fissures in the coating formed previously in the alkaline buffer. Rutin was 
retained efficiently inside AC coated pellets when tested at pH 3.0, 6.8 and 7.5 where at least 
84 % of the initial drug load was still present in the pellets after 5.5 h of dissolution testing. 
Previous studies indicate that coating consisting of these polymers is able to prolong the drug 
release efficiently not only at low but also at high pH values, since sodium alginate not 
dissolves in acidic medium but is soluble under the alkali conditions, while opposite trend is 
observed for chitosan (Elzatahry et al., 2009). On the opposite, rutin was released rapidly 
when pellets were subjected to the medium of pH 4.0 which is related to chitosan dissolution 
(Dvořáčková et al., 2011). From our results, it can be supposed that pellets will pass intact 
through the stomach and the small intestine, and when they reach the colon, chitosan in the 
pellets core will be dissolved under low pH conditions or degraded by colonic enzymes, 
resulting in colon-specific drug delivery.  
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Fig. IV.4: Drug released profiles from coated rutin (♦) and 5-ASA (▲) pellets in the 
continuous dissolution method. Data are shown as mean ± SD. 
 
 
5.  THERAPEUTIC  EFFICIENCY 
 
 Since IBD represent extremely complex disorders with multiple components overall 
63 models have been described to allow the examination of inflammatory processes as well as 
the evaluation of new therapeutic modalities (Hoffmann et al., 2002). Nevertheless, none of 
the current animal models may reproduce this human disease completely. In fact, simple and 
reproducible models involving only nonspecific inflammation exists for the testing of new 
anti-inflammatory drugs that may be used in patients and acquired findings are very 
appreciated whereas the cells, cytokines and inflammatory mediators involved in the 
nonspecific inflammatory phase of colitis seem to be common to multiple models, despite 
widely divergent mechanism of induction, and also occur in the mucosal lesions of patients 
with IBD (Elson et al., 1995). Hapten-induced model of colitis by the intraluminal instillation 
of a solution containing ethanol, e.g. a "barrier breaker" and TNBS, e.g. a contact sensitizing 
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allergen and covalently reactive compound was originally described by Morris et al. (1989), 
and is one of the most widely used model for the study of IBD, because of the immediate 
inflammation, high reproducibility and simplicity of the induction process (Hoffmann et al., 
2002). Rectal administration of TNBS results in acute transmural necrosis which is likely 
caused by oxidative damage and focal basal cryptitis. This is followed by chronic 
inflammation with a mononuclear infiltrate and marked thickening of the bowel wall. 
Moreover, in rats, segmental ulceration, focal fibrosis, stenosis and granulomas can occur 
(Elson et al., 1995). After inflammation induction, tissue damage increases and maximizes on 
the 2nd day, remains high until the 10th day when it starts dropping and colitis recovers 
completely over time. This spontaneous healing and no relapsing nature of inflammation 
differs this model from human IBD (Luchini et al., 2009). In our study, the TNBS rat model 
was chosen as well recognized experimental model that allows induction of colitis at an exact 
location and affords an opportunity to evaluate new treatments potentially applicable to IBD 
patients (Morris et al., 1989).  
 It is well known that increased local drug concentration can improve therapeutic 
efficiency and this highlights the importance of mucoadhesive systems able to retain a dosage 
form at the site of action in the treatment of IBD (Smart 2005). The most widely investigated 
group of mucoadhesives is hydrophilic macromolecules containing numerous hydrogen bond 
forming groups (Smart et al., 1984). Typical example is chitosan, a cationic polymer obtained 
by alkaline deacetylation of chitin, which is one of the most abundant natural polysaccharides 
largely available in the exoskeletons of shellfish and insects (Singla and Chawla, 2001). It has 
attracted much attention in the recent years in the pharmaceutical and medical fields owing to 
its favorable biological properties such as biodegradability (metabolization by lysozyme and 
colonic bacteria enzymes), biocompatibility and low toxicity (Pangburn et al., 1982). In 
addition to hydrogen bonds, free amino groups are available for ionic cross-linking with 
negatively charged sialic acid residues of mucin which results in mucoadhesion and longer 
residence time of the dosage form at the site of absorption (He et al., 1998).  In the line with 
this supposition, we incorporated chitosan into the pellets. These chitosan-core pellets showed 
efficient mucoadhesive properties in ex vivo bioadhesion testing and also provided higher 
drug metabolite concentration in the inflamed colonic tissue compared to chitosan free or 
Salofalk® Granu-Stix® pellets. Our results are in good accordance with earlier investigations 
revealing mucoadhesive properties of formulations containing chitosan. For instance, 
Takeuchi et al. (2005) observed the highest adhesive % of chitosan-coated among the three 
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different polymer-coated liposomes. Also, Wittaya-areekul et al. (2006) have demonstrated 
enhanced mucoadhesivity of chitosan coated alginate microparticles than the uncoated one.  
 5-ASA has become a standard therapy for mild-to-moderate IBD based on an 
extensive and long treatment history (Kornbluth and Sachar, 2010). On the other hand, rutin, 
naturally occurring flavonoid exhibited anti-inflammatory and anti-oxidant properties could 
be the subject of interest as a possible drug for the treatment of this chronic disorder (Guardia 
et al., 2001). Therapeutic efficiency of either 5-ASA or rutin loaded pellets was tested in 
experimental colitis in rats. Administration of pellets markedly decreased the colon/body 
weight ratio and myeloperoxidase activity in comparison with the colitis control group        
(Fig. IV.5). However there was no statistical difference among the treated groups. 
 
Fig. IV.5: Determination of colon/body weigh index (A) and myeloperoxidase activity 
(B) after final drug administration for n = 4 animals. *P < 0.05 compared with colitis 
control group. Data are shown as mean ± SD.   
 
 
 The results from this study revealed additional beneficial properties of bioadhesive 
chitosan-core pellets for colonic 5-ASA delivery. In this respect, the potential to increase drug 
residence time in the inflamed area may be a valuable tool to further optimize the therapy of 
IBD. Additionally, rutin pellets coated with mixed film composed of chitosan and alginate 
showed significant healing effect in experimental colitis comparable to 5-ASA pellets. This 
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could lead us to think that formulations based on natural components may be promising 
candidates in the treatment of IBD. With regard to the study of Mizoyama et al. (2004) 
reporting on inhibitory effect of flavonoids on 5-ASA N-acetylation, co-administration of 
rutin pellets together with 5-ASA preparations could provide increased tissue levels of 5-
ASA, decreased dose intake, more appropriate dosage schedule and thus ameliorate patient 
compliance in the treatment of this enigmatic disease. Likewise 5-ASA-rutin loaded pellets 
may represent interesting formulation for further investigations. 
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